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Prevotella melaninogenica, an anaerobic Gram-negative bacterium, is a member 
of the normal oral flora and is one of the most abundant anaerobic species found in 
respiratory specimens from individuals with cystic fibrosis (CF). Because of P. 
melaninogenica’s designation as a commensal, its role in CF disease pathogenesis and 
host immune response has been largely ignored.  
In our study of 61 CF patients at UNC hospitals, P. melaninogenica was cultured 
from 61% of adults and 57% of pediatric CF patients, and represented the most 
abundant strict anaerobe in both groups.  Lung function did not correlate with the 
presence or abundance of P. melaninogenica but there was an increased antibody 
response against P. melaninogenica in both adult and pediatric CF patients compared 
to non-diseased controls.  To explore innate host response, we characterized the 
structure and inflammatory effect of P. melaninogenica LPS.   P. melaninogenica lipid A 
structure is heterogeneous, with the most prominent form being diphosphorylated and 
penta-acylated. In THP-1 cells, P. melaninogenica LPS induced significantly less IL-8 
and IL-1β cytokine production than Pseudomonas aeruginosa LPS. We also showed 
that P. melaninogenica LPS could signal through a TLR4 independent pathway.  These 
results show the presence of P. melaninogenica in CF patients and its recognition by 
the human host. 
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From the tongue to the lung, P. melaninogenica must acquire nutrients to sustain 
life. The lung environment within chronically infected CF patients contains high levels of 
host iron proteins and pockets of anaerobic space. In vitro growth experiments 
demonstrated that heme or hemoglobin were sufficient iron sources for P. 
melaninogenica growth.  To identify the first step of acquisition, we sequenced the P. 
melaninogenica genome and searched for homologues of known hemoglobin receptors. 
We identified a comprehensive list of putative P. melaninogenica hemoglobin receptors.   
Together these studies characterize the prevalence of P. melaninogenica in CF 
infection, evaluate P. melaninogenica’s impact on the host and determine nutritional 
requirements, which will lead to a better understanding about the role of P. 
melaninogenica in CF. Continued research into anaerobic pathogens, in particular P. 
melaninogenica, will lead to improvement in treatment interventions to reduce the 
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P. melaninogenica Classification and Epidemiology 
 
Prevotella melaninogenica, previously Bacteroides melaninogenicus (subspecies 
melaninogenicus), is an anaerobic, black pigmented, Gram-negative bacterium 
belonging to the family Prevotellaceae (1). P. melaninogenica is a non-motile, catalase 
negative, saccharolytic bacterium that can produce an uncharacterized capsule (2, 3). 
P. melaninogenica is considered to be a member of the normal human oral flora and 
can be cultivated from the tongue, gingival crevice, saliva and plaque of healthy 
individuals (4-7). Initial reports (1950-90s) showed that P. melaninogenica only 
colonized the mouth following tooth eruption (8, 9), but more recently, P. 
melaninogenica has been isolated from the oral cavity of infants as young as two 
months of age (10, 11).   
 
P. melaninogenica infections 
P. melaninogenica has been described as a ‘potential pathogen’ because of its 
occurrence in disease sites throughout the body and its capacity to produce a variety of 
virulence factors (2, 12-14). In particular, P. melaninogenica is commonly cultured as 
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the sole infectious agent in ‘extra-oral’ abscesses such as vertebral osteomyelitis, 
pyomyositis, peritonsillar abscesses and vaginal mesh infections (15-19). However, 
closely related oral bacteria, such as Porphyromonas gingivalis and Prevotella 
intermedia have received more attention due to their established association with 
systemic diseases such as atherosclerosis, pneumonia, preeclampsia, cardiovascular 
disease, stroke, heart disease, and diabetes mellitus (20-22).  
In addition to single species infection,  P. melaninogenica is frequently cultured in 
the context of polymicrobial disease, including brain abscesses, pleuropulmonary 
infections, endocarditis, illicit drug injection sites, intra-abdominal infections, wound 
infections, necrotizing fasciitis, pyogenic infections, decubitus and diabetic ulcers (16, 
23-29). P. melaninogenica is also one of the most prevalent and abundant anaerobic 
species found in respiratory specimens from individuals with cystic fibrosis (CF) (12, 30-
37).  
 
Bacterial Synergism     
The presence of P. melaninogenica within complex bacterial populations raises 
the possibility that its growth at different body sites requires bacterial synergism, where 
the presence of other bacterial species could improve the likelihood of colonization by 
this otherwise fastidious species. Pathogenic bacterial synergism occurs when a 
polymicrobial community is more destructive to the host than any single member of the 
community.  This type of synergism is often the result of microbial interactions such as 
nutritional sharing or interspecies quorum sensing, that can alter bacterial gene 
expression, growth and virulence capabilities.  
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In its simplest form, bacterial synergism has been studied in two species model 
systems.   For example, it has been shown that virulence genes of the opportunistic 
pathogen Pseudomonas aeruginosa are upregulated in the presence of oropharyngeal 
isolates of either Streptococcus or Staphylococcus species. This modulation of 
virulence factors was found to be partially due to an increase in autoinducer-2 signaling 
and competition for iron (38).  Furthermore, experiments using an abscess model 
showed a greater host inflammatory response to mixed species infection compared to 
single species infection (39, 40).  Additional studies have shown that there are growth 
benefits to Bacteroides species (Bacteroides fragilis and Bacteroides asaccharolyticus) 
when present in a polymicrobial abscess model of infection (41).  It is believed that 
Bacteroides species specifically benefit from nutrients produced by the community. 
Similarly, it has been shown that P. melaninogenica, can acquire vitamin K, an essential 
growth factor, when grown in the presence of Staphylococcus aureus (42). Because of 
its ability to survive and grow in polymicrobial infections, P. melaninogenica likely 
contributes to the pathogenic potential of these communities. Ultimately, bacterial 
virulence potential in the context of polymicrobial conditions depends on the virulence 
characteristics of the individual species, the host response, and environmental 
conditions within the infected niche (20, 43, 44).   
 
Virulence Characteristics of P. melaninogenica 
In the human host, initial colonization by P. melaninogenica is aided by fimbrial 
hemagglutinin, which serves as an epithelial cell adhesion (45).  Host nutrients required 
for P. melaninogenica growth are liberated by hemolysin and fibrinolysin (46). To protect 
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against host detection and antimicrobial factors, P. melaninogenica isolates can 
produce both IgA and IgG proteases (47-49), a β-lactamase (24), and a polysaccharide 
capsule. To further modulate the immune system, P. melaninogenica produces a 
neuraminidase, which has been shown to cleave sialic acid from host surface 
glycoproteins and leukocytes to disrupt immune recognition and trigger degradation of 
host proteins (50). Once colonization is established, P. melaninogenica can further 
damage host tissue through the production of collagenase (11, 51) and a lipase, both of 
which contribute to abscess formation (11). 
 
Host Immune Response 
 
P. melaninogenica is primarily regarded as a member of the oral commensal 
flora; consequently its role in disease pathogenesis and host immune response has 
been largely ignored.  However, with the use of molecular-based detection methods, P. 
melaninogenica is frequently identified in abscesses and infected tissues throughout the 
body. Despite its association with a wide-variety of infections, little is known about its 
contribution to disease progression. 
 
Innate Immunity 
Bacterial lipopolysaccharide (LPS) is a key bacterial factor that impacts host 
immune response. Pathogen associated molecular patterns (PAMPS), including 
bacterial LPS, alert the immune system to the presence of bacterial invaders through 
pattern recognition receptors (PRRs), on immune cells such as macrophages and 
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dendritic cells. LPS is composed of three distinct components: lipid A, core 
polysaccharide, and O antigen.  The covalently bound lipid component of LPS, lipid A, 
constitutes the hydrophobic outer leaflet of the Gram-negative outer membrane and is 
responsible for LPS toxicity. It is traditionally composed of a glucosamine disaccharide 
backbone with acyl chains of varying length and number and the presence or absence 
of phosphate groups.  Length of the fatty acid chains and the addition of phosphate 
groups can greatly impact the toxicity of lipid A. The core polysaccharide, attached to 
lipid A, is composed of heptose and 2-keto-deoxyoctulosonic acid (KDO).  The O 
antigen component, which is the outermost portion and hydrophilic part of the LPS, is 
made up of repeating subunits of 3 to 5 sugars that vary between species and even 
strains. The presence of O antigen is responsible for the ‘smoothness’ characteristics of 
the bacterial colonies and helps to confer resistance to phagocytosis. LPS, which is 
released during growth and death of a bacterium, has been shown to induce 
macrophages to produce reactive oxygen species and to activate antigen presentation 
and cytokine response pathways. Traditionally, LPS activates the alternative 
complement pathway.  
Historically, P. melaninogenica was a member of a group of species collectively 
designated as Bacteroides melaninogenicus. Other members of this closely related 
group included Porphyromonas gingivalis, Prevotella intermedia and Prevotella 
nigrescens. P. gingivalis has been the most studied species of this group because of its 
role in periodontal disease.  LPS from P. gingivalis has been demonstrated to stimulate 
bone resorption, adhere to erythrocytes and attachment to oral cavity surfaces (52). P. 
gingivalis lipid A is penta-acylated and monophosphorylated and has been consistently 
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shown to exhibit weak pro-inflammatory properties (endotoxicity) (53). Most reports 
have shown that P. gingivalis LPS is significantly less inflammatory than E. coli LPS 
(54), while some studies suggest P. gingivalis LPS is equal or even more 
proinflammatory than that of E. coli (55, 56). It has been suggested that the differences 
reported in these studies are due to alteration in LPS structure that result from different 
growth conditions and extraction techniques (57). P. gingivalis LPS has been shown to 
stimulate IL-1β, IL-6, IL-8, IL-10, IL-12, TNFα, IGF1 and NFĸB expression and 
production in THP1 cells (58, 59) as well as, IL-1β, TNFα and IL-8 in polymorphonuclear 
neutrophils (54, 60, 61).  Because controversy still remains about the magnitude of P. 
gingivalis LPS cytokine response, it is difficult to predict the impact of P. melaninogenica 
LPS on the host inflammatory response.  Foundational studies need to be completed to 
thoroughly characterize the structure and inflammatory effect of P. melaninogenica.     
 
Toll like receptors:  
An important aspect of the inflammatory cytokine response to bacterial infection 
is due to a cascade of signaling pathways initiated by Toll like receptors (TLRs), which 
are transmembrane receptors that respond to PAMPS and have a primary role in innate 
immunity initiation (62). The TLR response to bacterial products occurs by both 
transcriptional and post translational mechanisms.  TLR activation initiates MyD88 and 
TRIF signaling cascades that activate mitogen-activated protein kinase kinase kinases 
(MAP3Ks) and lead to NFĸB activation (63). NFĸB induces transcription of inflammatory 
cytokines genes such as IL-8, IL-6, IL-1β and TNFα. Once produced, these cytokines 
alert other cellular components of the immune system.  The post-translational signals 
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stem from cytosolic pattern receptors that stimulate inflammasome components that in 
turn activate caspase 1 to cleave IL-1β and IL-18 into their active forms (58).  
Traditionally, bacterial LPS binds to an accessory protein, lipopolysaccharide-
binding protein, which then triggers the CD14-MD-2-TLR 4 complex and activates TLR 
4 LPS dependent responses (62, 64, 65). Other TLRs, specifically TLR 2, are known to 
recognize bacterial products such as peptidoglycan, lipoteichoic acid and lipoproteins.  
Number and length of lipid A acyl chains in addition to their branched structure can lead 
to differential TLR signaling. Confusion in the field of LPS dependent TLR signaling has 
been clouded by lipoprotein contamination of LPS preparation causing TLR 2 activity 
leading researchers to conclude TLR 2 dependence (66).   
Bacteroides species, such as P. gingivalis, demonstrate unique structure 
changes dependent on environmental cues (57, 67-69).  In particular, environmental 
heme concentration modifies the activity of lipid A 1-dephosphorylatases that leads to 
an alteration in phosphate group attachment to the glucosamine portion of lipid A. This 
change in structure modulates the ability of P. gingivalis to stimulate TLR 4 (53, 57, 62, 
69). In these reports, P. gingivalis LPS signals through TLR 4 either acting as an 
agonist in low heme (1 mg/ml) or an antagonist in high heme (10 µg/ml) (68-70).  
P. gingivalis LPS response is controversial due to the questions that still remain 
about the variability of P. gingivalis cytokine response compared to other more 
traditional agonists (i.e. E. coli LPS) and the inconsistent reports deciphering P. 
gingivalis TLR signaling pathways. Despite the similarities and phylogenetic relationship 
between P. melaninogenica and P. gingivalis, the controversies surrounding P. 
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gingivalis LPS structure and properties make it difficult to make predictions about P. 
melaninogenica TLR signaling.  
 
P. melaninogenica innate immune response 
Characterization of host immune response to P. melaninogenica has been limited 
in the past because of its inclusion under the grouping of B. melaninogenicus, which is 
now recognized to have encompassed multiple species including P. gingivalis. 
Consequently, reports prior to 1990 have been considered in this review only if a 
specific P. melaninogenica strain was clearly specified.   
P. melaninogenica LPS studies are incomplete; and have only focused on O 
antigen and the hemagglutination properties of total LPS preparations. P. 
melaninogenica O antigen appears to have similarities to O antigen from Prevotella levi 
(71) which is involved in evasion of phagocytosis. Total LPS preparations from P. 
melaninogenica have been shown to have less hemagglutination activity compared to 
other Prevotella species such as P. intermedia and P. denticola (52).  Because of the 
role of LPS in initiating bacterial infection and host immune recognition a more thorough 
characterization of P. melaninogenica LPS is needed.  
To investigate the role of P. melaninogenica in infection, total cellular lysates 
were shown to stimulate a low level cytokine response (IL-1α, IL-6 and TNF α in human 
monocytes and human gingival fibroblasts) through a TLR 2 and not TLR 4 signaling 
pathway (72, 73).   Consistent with this report, whole formalin-fixed P. melaninogenica 
have also been shown to signal through TLR 2 when tested in cell lines over expressing 
either TLR 2 or TLR 4 (73).  In addition to its apparent TLR 2 agonist properties, P. 
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melaninogenica could be a TLR 4 antagonist. In a study designed to model the 
polymicrobial environment of COPD, P. melaninogenica lysates dampened 
Haemophilus influenzae TLR 4 signaling in dendritic cells leading to a decrease in IL-12 
response (74).  Additionally, experiments investigating the effect of  ‘normal flora’ to 
pathogenic bacteria immune evasion found that P. melaninogenica supernatants, 
representing normal flora, impaired the phagocytosis of the pathogen, Proteus mirabilis, 
by polymorphonuclear leukocytes  (75).  These studies represent the effect of a 
complex mixture on cellular response, but do show how P. melaninogenica could have 
a potential impact on innate immune response and the immune stimulation by other 
pathogens.   
 
Adaptive Immunity 
Among the five classes of immunoglobulins, immunoglobulin G (IgG) makes up 
the majority of serum antibodies and is commonly used as a predictive marker for 
infection (76). IgG aids phagocytosis through opsonization and complement activation. 
In the case of bacterial infections, the development of a specific acquired immune 
response is characteristic of pathogen exposure and bacterial burden (77-79).  Elevated 
antibody titer, (specifically IgG titer) for specific pathogens, has been used to diagnose 
infections such as syphilis (80), and human papilloma virus (81).  
 Infections by oral bacteria have been shown to stimulate a humoral response, 
specifically an increase in serum IgG to bacterial antigens (76, 82). Increased serum 
IgG titers for periodontal pathogens are used as diagnostic markers of periodontitis (76, 
83) and are used to direct prophylactic therapy. In addition, treatment outcomes, 
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including the reduction of bacterial load, correlate with a reduction of serum IgG titer to 
specific pathogens (76). 
 IgG levels to P. melaninogenica have been measured in a small number of 
studies. P. melaninogenica IgG titer has been shown to be increased in rheumatoid 
arthritis patients compared to healthy controls (2). Also, P. melaninogenica IgM (an 
early response antibody) is increased in ventilator-associated pneumonia patients 
compared to controls (78). Based on these findings, immunoglobulin titer can be an 
effective tool in evaluating infection by Prevotella species (78).    
 
Immune response to commensal bacteria 
The presence of commensal bacteria in the body is a constant stimulus to the 
immune system and requires the host to produce an immune response, both cytokine 
and antibody, to keep the commensal contained.  The host response against 
endogenous bacteria becomes increased when the bacteria spread to non-traditional 
locations in the body.   
In the oral cavity, commensal bacteria stimulate low-level inflammation that 
contributes to oral health.  Specifically, low levels of IL-8 induce the chemotaxis of 
neutrophils into the gingivalis crevice to patrol for bacterial pathogens (13). In other 
parts of the body, the low level stimulation by commensal bacteria aids in the 
development and maintenance of the immune innate system as seen in experiments 
with germ-free mice (84). In addition, endogenous bacteria, like Staphylococcus aureus 
or Pseudomonas aeruginosa, can cause opportunistic infections when the host immune 
defenses are impaired or overwhelmed (85, 86).   
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Nutritional Requirements of P. melaninogenica 
Iron 
Iron, commonly observed in one of two states (Fe2+, Fe3+), has a extensive redox 
potential, making it a critical enzyme cofactor in the metabolism of amino acid and 
biosynthesis of nucleotides, vital processes in all organisms (87, 88). For aerobic 
bacteria, iron is critical for respiration, where it serves as a cofactor for cytochromes 
involved in electron transport (89). In contrast, anaerobes use iron-sulfur compounds 
and fumarase, in addition to other iron containing molecules such as catalase and 
peroxidase, for protection against superoxide and in the production of ATP through 
pyruvate aided fermentation (90, 91).  
 
Iron in the host:  
Iron is a necessary nutrient for basic cellular metabolism; however, because of its 
reactivity it can be harmful if not complexed. Under reducing (anaerobic) conditions or at 
low pH, ferrous iron (Fe2+) is the dominant iron form. Ferrous iron is more soluble than 
ferric iron (Fe3+) making it more toxic and able to pass through semi permeable 
membranes. Iron can catalyze the Fenton Reaction which leads to the production of 
reactive oxygen species that damage cellular components (92). Because of the 
necessity for iron and its intrinsic toxic potential, there is a delicate homeostasis needed 
to balance iron abundance and scarcity in the host (93).  Free iron in a mammalian host 
is as low as 10-24 M (87, 93, 94) due to the presence of high affinity iron binding proteins 
such as ferritin (inside cells), lactoferrin (mucus secretions), hemoglobin (blood) and 
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transferrin (bodily fluid such as blood). The majority of iron in the human body is 
sequestered in hemoglobin in the form of heme (94).  
 
Bacterial Iron Regulation 
To survive in the host where iron is scarce, bacteria have developed tightly 
controlled mechanisms to alter the expression of iron acquisition proteins such as 
siderophores, degradative enzymes, hemolysins, and hemagglutination (46, 89, 95-97) 
in response to iron abundance and scarcity. In many bacteria, iron acquisition is 
regulated by the ferric uptake regulator (Fur), which represses transcription of iron 
transport and scavenging genes when intracellular iron concentrations are sufficient.  
Available intracellular iron binds to Fur, facilitating the formation of Fur dimers.   The 
dimer complex binds to the promoter region of iron regulated gene through recognition 
of specific (Fur box) sequences (98-100). The DNA bound complex hinders access of 
RNA polymerase. Under iron limiting conditions, Fur controlled genes involved in iron 
acquisition and storage become derepressed (94, 99, 101-104).  
 
Porphyromonas and Prevotella heme requirements 
Bacterial organisms require iron to sustain vital cellular processes but some 
microbes, in addition to iron, require iron in the form of heme.  Heme, which represents 
a stable and highly usable form of iron, consists of iron complexed inside a porphyrin 
ring structure. Heme can be used directly as an enzyme cofactor or it can be broken 
down to release molecular iron.    
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 In bacteria, the heme molecule is essential for electron transport and the activity 
of several metabolic enzymes (100, 105).  In P. gingivalis, heme is a cofactor of the 
cytochrome b subunit of fumarate reductase, which plays a role in metabolic energy 
production (94, 102, 106, 107).  Also a heme derivative, µ-oxo bishaem, is stored on the 
outer surface of many Bacteroides species and produces the characteristic black 
pigment associated with P. gingivalis (108) and other black pigmented Bacteroides such 
as P. melaninogenica and P. intermedia when exposed to oxygen.  The surface 
localized heme derivative is used for protection against oxygen radicals, and is thought 
to promote local environmental anaerobiosis (108-110).  
Many microbes can produce heme through a complex in vivo heme biosynthesis 
pathway; however, all bacteria in the genera Bacteroides lack the enzymes to 
synthesize their own heme. Specifically, P. gingivalis lacks genes encoding 5-
aminolevulinic acid synthase and porphobilinogen deaminase (111) and must rely on 
exogenous sources of this molecule.  
P. gingivalis can acquire heme from host heme binding proteins such as 
hemoglobin and myoglobin or enzymes that use heme as a cofactor such as catalase 
and myoglobin.  In addition, P. gingivalis can use non heme based iron sources such as 
inorganic iron, and iron stored in transferrin and lactoferrin (98, 112, 113). Prevotella 
spp., like P. intermedia cannot survive without protoporphyrin IX (PPIX) based iron such 
as heme, hemoglobin and myoglobin, cytochrome c and catalase (114, 115). Inorganic 
forms of iron including ferric chloride, ferric citrate, ferric nitrate, and ferric ammonium 
citrate do not support growth of P. intermedia (110, 114).   
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P. melaninogenica, like other Bacteroides species including P. intermedia, 
requires heme for growth (42). P. intermedia and P. gingivalis represent closely related 
species that have differing abilities to use iron and heme based sources. Further 
research is necessary to determine the iron requirements for P. melaninogenica and its 
capacity to utilize host-based iron sources.  
 
In vivo heme acquisition  
 The majority of useable iron in the human body comes in the form of heme, 
complexed inside of hemoglobin, myoglobin or haptoglobin. Bacteria have successfully 
overcome this limitation by using two mechanisms that remove heme from host heme-
containing proteins: 1) production of hemophores, which are secreted proteins that bind 
heme and are subsequently recognized by a cognate bacterial surface receptor, and 2) 
direct extraction of heme via high affinity heme- or hemoglobin-binding bacterial surface 
proteins (116).  Some bacteria encode only high affinity hemoglobin receptors whereas 
others use a combination of receptors and hemophores.  In addition, there are 
proteolytic enzymes thought to play a role in releasing heme from heme-containing host 
proteins (94).  In polymicrobial communities, bacterial iron acquisition mechanisms, 
such as hemolysins that rupture red blood cells, can be a source of interspecies cross 
feeding. (89, 117-120). High affinity hemoglobin receptors are important for host 
colonization and have been implemented as a vaccine target for Haemophilus ducreyi 
to prevent bacterial diseases such as chanroid and against E. coli as treatment for 
urinary tract infections (121, 122).  
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Heme acquisition by Gram-negative bacteria is an orchestrated process that 
involves heme binding to an outer membrane receptor (in some cases aided by 
hemophore) followed by a series of steps that transfer heme through the outer 
membrane and periplasm and into the cytoplasm where it is used as a cofactor itself 
(e.g. in cytochromes or catalases) or is broken down for its iron component (123). 
Bacterial hemoglobin receptors form a beta barrel confirmation in the outer membrane 
and have characteristic domains (FRAP and NPNL signatures) and specific histidine 
residues that aid in the removal of heme from hemoglobin (116, 124-127). Once bound, 
heme is transported through the beta barrel channel of the receptor by the energy 
derived from the proton motive force associated with the binding of the TonB complex to 
the receptor. Binding of the two proteins is mediated through a ‘TonB box’, which is a 
conserved sequence present in the N-terminal periplasmic portion of the outer 
membrane receptor (128, 129). Once heme enters the periplasm, it is bound and 
transported by a heme permease to the inner membrane, where an ABC transporter 
can then transport it to the cytoplasm (130).  
The mechanism of heme/hemoglobin acquisition has been investigated to some 
degree in oral anaerobes; however, the molecular details await further study. Both P. 
gingivalis and P. intermedia have heme acquisition systems that involve proteolytic 
degradation of erythrocytes and heme-binding receptors (94). Specifically, P. intermedia 
has been shown to lyse erythrocytes, degrade hemoglobin and bind both heme and 
hemoglobin through an undefined receptor (110, 115, 131, 132).  Additionally, several 
P. gingivalis hemoglobin receptor complexes including HmuR, Tla and HemR (102, 133-
135) have been identified.  For P. melaninogenica, no outer membrane receptor has 
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been characterized but a key to its in vivo growth could be its ability to promote 
aggregation and lysis of red blood cells (46), which suggests that it is capable of freeing 
hemoglobin for bacterial binding and eventual heme uptake. The proteins involved in 
the subsequent steps in heme acquisition have yet to be identified.  
 
CF Lung Infection 
Mechanism 
The most common fatal genetic disease in the Caucasian population is cystic 
fibrosis (CF).  CF is inherited in an autosomal recessive pattern and occurs in 
approximately 1 in 2,500 live births with about 30,000 recognized CF patients in the 
United States (136).  CF disease is due to dysfunction of the epithelial membrane 
protein cystic fibrosis transmembrane regulator (CFTR). The most common CFTR 
mutation associated with CF results in a deletion of phenylalanine at amino acid position 
508 resulting in protein misfolding (137-139). CFTR is a cyclic AMP-dependent chloride 
channel and a negative regulator of the epithelial sodium channel ENaC (138-140). 
Dysfunctional CFTR causes an imbalance of sodium absorption and chloride ion 
secretion on mucosal surfaces, affecting many mucosal organs including the lungs, 
pancreas, skin and the reproductive system (141). In CF, liquid dysregulation in the 
lungs is of considerable importance because it compromises mechanical clearance and 
host immune homoeostasis. Hyperabsorption of sodium and water at the apical surface 
of bronchial epithelium reduces periciliary liquid (PCL) volume resulting in increased 
mucus viscosity and impaired ciliary function (142-145). This clearance defect combined 
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with mucin hyper-secretion by goblet cells leads to thickened mucus in the conducting 
airways of CF patients.   
Inefficient clearance of mucus in the CF lung provides an optimal colonization 
niche for a diverse assembly of bacteria (146-148). From infancy to adulthood, CF 
patients experience a decline in lung function caused by persistent bacterial infection 
and unrelenting pulmonary inflammation (149). Over a period of years, an accumulation 
of bacterial products and cellular debris produces irreversible airway damage and 
inflammation that ultimately leads to respiratory failure and death, with an average life 
expectancy of 37 years.   
 
CF Treatment: 
Treatment of CF starts early in life through therapeutic bronchodilators, anti-
inflammation treatments and antibiotics. Antibiotic treatment is based on aerobic culture 
of bronchoalveolar lavage fluid (BALF) and sputum. BALF is captured through an 
invasive procedure where sterile saline is released into the conducting airways through 
a bronchoscope then collected. Induced and spontaneous sputum samples are 
collected after the patient coughs up thick mucus, believed to be from the bronchial 
airway surface (150). Contamination of these methods is evaluated by comparison of 
organisms recovered from saliva samples. These aerobic culture methods are used to 
guide clinicians in appropriate antibiotic treatment for individual patients. However, 
aerobic culture methods are inadequate for representing all members of the bacterial 
community, in particular fastidious organisms and anaerobic bacteria (12). Antibiotics 
aimed at classical aerobic pathogens including P. aeruginosa, are largely ineffective in 
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clearing bacterial infection (142, 151, 152). For example, there is no significant change 
in aerobic bacterial load comparing episodes of disease exacerbation and subsequent 
recovery periods (38) or testing pre and post antibiotic treatment (153). These 
discrepancies suggest that aerobic culture does not provide the full picture of CF 
pathogenesis. There is now growing evidence that pulmonary infections in CF should be 
treated as a polymicrobial infection with aerobic, anaerobic and fungal components 
(146).   
 
Key aerobic bacteria in the CF microbiome   
By as early as 3 months, nearly 40% of infants diagnosed through neonatal CF 
screening have a lower respiratory bacterial infection (154). Aerobic culture based 
techniques and quantitative PCR (qPCR)  for the highly conserved bacterial 16S rRNA 
gene from CF samples (BALF, induced sputum, spontaneous sputum) illustrate that CF 
affected children are colonized by Staphylococcus aureus, Streptococcus spp, 
Haemophilus influenzae and Pseudomonas aeruginosa (38, 155, 156). As CF patients 
age, the diversity of the bacterial community decreases and the majority of CF patients 
become chronically colonized with P. aeruginosa (153, 157, 158). During the transition 
between acute and chronic infection, P. aeruginosa acquires mutations in lasR leading 
to antibiotic resistance and a metabolic transition to use host-associated amino acids 
(159). Another hallmark of chronic P. aeruginosa colonization in the CF lung is the 
cultivation of isolates encased in an alginate exopolysaccharide (160, 161). This state is 
commonly called mucoidy and correlates to a decline in clinical outcome for individuals 
with CF (142, 162). Mucoid P. aeruginosa are thought to exist in a biofilm-like state 
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within mucus plugs, allowing the bacteria to be highly resistant to phagocytosis, 
antibodies and antibiotic treatment (143, 151, 163). There is direct evidence of P. 
aeruginosa enmeshed in alginate biofilm aggregates in CF lung samples (147). In 
adults, the bacterial community within the biofilm may also include other aerobes such 
as Streptococcus milleri species (164), Burkholderia cepaci, Stenotrophomonas 
maltophilia and multiple fungal species (165). As CF lung disease progresses the 
successful growth of P. aeruginosa is aided by the ability of P. aeruginosa to adapt to 
other bacteria and environmental changes including the reduction of oxygen in CF 
mucus plugs (166).  
 
CF anaerobic niche 
Direct measurements of the oxygen gradient in CF mucus plugs range from 180 
mmHg outside to 2.5 mmHg inside the plug, demonstrating a significant drop in oxygen 
and near anaerobic conditions within the airway mucus (166). The exact mechanism of 
oxygen depletion within CF mucus plugs has not been confirmed but there are multiple 
hypotheses involving accelerated O2 consumption either by the lung epithelium, 
immune cell respiratory bursts or elevated bacterial respiration (141). P. aeruginosa and 
other facultative anaerobes that are present in the lungs of CF patients can live 
anaerobically in the presence of an appropriate terminal electron acceptor, such as 
arginine (163, 166-170).  
Because anaerobic bacteria have been documented in other polymicrobial 
infections of the lung such as pneumonia, lung abscesses and empyema, these 
bacteria could have significant relevance in pulmonary infection in CF (37, 148). CF 
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samples processed using anaerobic culture techniques and other unbiased molecular 
methods such as 16s rRNA gene profiling by microarray, pyrosequencing and reverse 
transcription terminal restriction fragments length polymorphisms (TRFLP), have 
revealed the presence of strict anaerobes (29-32, 34-37, 148, 156, 164, 165, 171-173). 
Because of this, many have hypothesized that anaerobes may play a role in the 
pathogenesis of CF airway disease (12, 31, 37, 38, 142, 148, 171). Tunney et al. (2008) 
noted that the most prevalent strict anaerobes isolated from sputum were Prevotella 
species, including P. melaninogenica. Anaerobic bacteria in this study were isolated in 
high numbers (104-109 CFU/g sputum) in 64% of adults and, in some cases, were 
present in higher numbers than P. aeruginosa (37). The prominence of  Prevotella is 
consistent with past studies involving anaerobic culture techniques and molecular based 
approaches (12, 29-32, 34-37, 148, 156, 164, 165, 172-175). It has been suggested that 
anaerobes, in particular Bacteroides spp. (now Prevotella spp., Porphyromonas spp. 
etc), could be of clinical importance in CF (148) and potentially pathogenic (30, 32, 37). 
Of the Prevotella species enumerated in CF samples, P. melaninogenica is the most 
common anaerobe reported using culture independent and anaerobic culture 
techniques (37), and it is frequently present in high numbers (12, 30-32, 34-36). Despite 
the cumulative evidence for the presence of anaerobic bacteria in the CF lung based on 
analysis of sputum and BALF, two studies of explanted lung specimens suggested that 
oral anaerobes are not present in lower airway but instead are found in upper airway 
specimens such as the trachea due to ‘oral contaminants’ (174, 176).  
 
CF immune response  
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In CF, when bacteria colonize the lung, the host responds with an influx of 
polymorphonuclear leukocytes followed by cytokine and antibody production (138, 140, 
141, 146, 149, 177-179). Studies have shown that this CF characteristic response of 
PMNs is not a CFTR dependent response as some had speculated (177, 180). The 
immune response of CF patients is defined by ineffective killing of bacteria colonizing 
the lung, and the development of chronic inflammation that leads to lung dysfunction 
and respiratory failure. These processes are responsible for the majority of CF deaths 
(37, 141, 169). The exact initiation events leading to CF airway inflammation are the 
subject of debate, in part, because of the complexity of CF pathogenesis and 
inconsistent experimental results.  Further studies investigating cytokine response 
shows that there is significantly more IL-8 and neutrophils in BALF from CF children 
than children with other non-CF respiratory disease (179). Additionally, studies using 
sputum and BALF samples from CF adults show an increased number of neutrophils, 
increased levels of the pro-inflammatory cytokines TNF α, IL-1β, IL-6, IL-8, and reduced 
levels of the anti-inflammatory cytokine IL-10 (181-183); this response is  thought to be 
mediated by TLR-dependent pathways (137, 184).   
In addition to innate inflammatory responses, the adaptive immune system in CF 
patients also produces a response against bacterial pathogens enmeshed in CF mucus 
plugs.  In CF, elevated levels of P. aeruginosa-specific IgG antibody have been noted 
and been used for diagnostic purposes (185). P. aeruginosa infection occurring in 
subjects as young as 6 months have been diagnosed using P. aeruginosa specific IgG 
serological testing (185-187).  Consistent with this finding, a high level of P. aeruginosa 
specific IgG antibodies correlate with negative clinical outcome (185).   
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Iron in the CF lung 
The lung environment within chronically infected CF patients contains higher 
levels of iron compared to the lungs of healthy patients (89, 150, 158). Significant 
amounts of iron have been detected in sputum from CF patients in the form of ferritin, 
lactoferrin, transferrin and small amounts of hemoglobin (89). In an unpublished study, 
there was more than twice the amount of hemoglobin and heme in CF BALF than in 
asthmatic patients; ten times more than healthy individuals (188). The underlying cause 
of elevated iron in the CF lung is thought to be from micro-hemorrhage, inflammation 
(189), transferrin/lactoferrin proteolysis and release of intracellular iron stores from CF 
airway epithelial cells (93, 190). Additionally, the iron present in the CF lung is predicted 
to be more soluble (and therefore better available for bacterial uptake) because the pH 
of the lung is more acidic (5.8) in CF patients compared to healthy controls (6.1) (191).  
 
The role of P. melaninogenica in CF lung infection 
Despite evidence that anaerobic bacteria are part of the polymicrobial community 
in the CF lung, the question of their clinical relevance remains unanswered.  The role of 
anaerobes in CF pathogenesis can be thought of in two ways:  1) the anaerobes 
themselves could be pathogenic, and/or 2) the presence of anaerobes could influence 
the pathogenicity of the bacterial community. For the latter, the presence of additional 
bacteria could impact host inflammation initiated by the pathogenic agent (e.g. P. 
aeruginosa) (192) or provide a source of antibiotic resistance genes that could alter the 
resistance properties of the community. There has been suggested synergism between 
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P. aeruginosa and anaerobes in several cases (28, 39, 41). Bacteroides species 
including Prevotella are known to produce quorum-sensing signaling molecules and 
thus have the potential to affect the virulence of P. aeruginosa. Further work needs to 
be done in this area comparing P. aeruginosa to prominent anaerobic species.  
Here, we will explore the contribution of P. melaninogenica, which is the most 
commonly cultured anaerobic bacterium in the CF lung, to CF pathogenesis. In chapter 
2, we investigate the prevalence and abundance of P. melaninogenica in a cohort of 
UNC hospital CF patents and test P. melaninogenica reactive antibody response as a 
measurement of bacterial burden and exposure. This study is aimed at determining 
whether host response to a nontraditional CF associated bacterium is different in CF 
patients compared to non CF individuals.  In chapter 3, we determine the structure and 
inflammatory properties of P. melaninogenica LPS, the most toxic part of gram-negative 
outer membrane. In this chapter, we will examine the effect of P. melaninogenica LPS 
on a human monocytic cell line and determine TLR signaling pathways. Chapter 4 
focuses on how P. melaninogenica survives in the CF lung, specifically determining its 
ability to acquire iron from host sources and the mechanism for heme acquisition.  
My goal is not only to report and confirm the presence of anaerobes in CF but to 
provide understanding to the clinical relevance of P. melaninogenica. My findings may 
provide the justification for new treatment options to help patients with severe CF lung 
disease. New avenues for research in anaerobic bacterial pathogenesis will lead to 
knowledge about treatment interventions to reduce the severity of CF lung disease. My 
dissertation has immediate clinical significance in terms of applying new understanding 
to developing novel therapeutic approaches.  
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 Chapter 2: 
 
Prevotella melaninogenica, an oral anaerobe, in chronic cystic 




Recent microbiome studies suggest that the airways of individuals with cystic fibrosis 
(CF) are colonized by a complex microbiota, including strict anaerobes that traditionally 
inhabit the oral cavity. Prevotella species, including P. melaninogenica, are consistently 
the one of the most prevalent members of the CF microbiome; however, their clinical 
significance outside the oral cavity is unclear. Our study aims to elucidate whether P. 
melaninogenica contributes to CF disease pathogenesis by comparing P. 
melaninogenica culture status in adult and pediatric respiratory specimens with clinical 
measures of disease (FEV1%, CRP) and P. melaninogenica reactive antibody titer. 
Anaerobic, microaerophilic and aerobic culture techniques were used to culture sputum 
and BALF samples from 28 adult and 33 pediatric CF patients. Bacterial 16S rRNA 
gene sequence alignments were used for identification. FEV1% measurements were 
collected from CF patients. ELISA based methods were used to determine CRP levels, 
P. melaninogenica reactive antibody titer and total IgG response in our CF patient 
cohort, healthy volunteers and disease controls. P. melaninogenica was a prevalent and 
abundant member of the CF airway microbiota in CF adults and children.  Using clinical 
41 
data collected and serological measurements there was no correlation in FEV1% and 
CRP values of adults.  There was a significantly higher P. melaninogenica reactive 
antibody response in CF adult and child patients compared to controls.  
 
Introduction 
Cystic Fibrosis (CF) is the most frequent lethal genetic disease in the Caucasian 
population. CF is caused by mutations in the cystic fibrosis transmembrane regulator 
(CFTR) gene that ablate or alter CFTR function. CFTR dysfunction leads to airway 
surface liquid hyperabsorption and defective mucociliary clearance (1). Mucus stasis 
creates a favorable environment for bacterial colonization, which leads to chronic 
pulmonary inflammation and ultimately lung failure (1).  In addition to a gradual decline 
in lung function over time, most CF patients also experience periodic acute pulmonary 
exacerbation, which is characterized by increased disease symptoms and a rapid 
decline in lung function requiring hospitalization and intravenous antibiotic treatment (2). 
In CF, antibiotic maintenance therapy and treatment of exacerbations is guided by 
aerobic bacterial culture of expectorated sputum or bronchoalveolar lavage fluid (BALF) 
and bacterial susceptibility testing (3, 4). Aerobic culture-based studies indicate CF 
airways infection follows a predictable succession, with Haemophilus influenzae and 
Staphylococcus aureus dominating early in life and Pseudomonas aeruginosa and 
members of the Burkholderia cepacia complex becoming the most prevalent pathogens 
later in life (5-7). 
Recent studies by several groups, enumerated strict anaerobes when processing 
CF samples (sputum, BALF) anaerobically and using unbiased molecular based tools 
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such as quantitative PCR (qPCR) of 16S rRNA gene (5, 8-20). In Tunney et. al 2008, 
anaerobic bacteria have been isolated in high numbers (104-109 CFU/g sputum) in adult 
sputa samples and in occurred at higher levels than P. aeruginosa.  Anaerobic bacteria, 
like in other polymicrobial infections such as pneumonia, lung abscesses and 
empyema, could have relevance in CF (19, 21, 22). Also the occurrence of anaerobes 
has been found to correlate with the occurrence of P. aeruginosa (5, 19).  It has been 
suggested that anaerobes, in particular Bacteroides spp. (now Prevotella spp., 
Porphyromonas spp. etc), could be potentially pathogenic and of clinical importance in 
CF (4, 14, 17, 19, 21).  
Prevotella melaninogenica is one of the most common strict anaerobes reported 
in recent molecular-based CF airway microbiome studies. The presence of P. 
melaninogenica in CF airway specimens has been confirmed by culture independent 
and anaerobic culture techniques of CF samples (13, 15, 17, 19, 23). P. melaninogenica 
is a black pigmented Gram-negative bacterium known to produce several virulence 
factors such as a capsule, hemolysin and a variety of secreted proteases (24-26). While 
P. melaninogenica is typically considered a member of the normal human oral flora, it is 
frequently cultured from polymicrobial infections sites including brain abscesses, 
pleuropulmonary infections, intra-abdominal infections, wound infections and necrotizing 
fasciitis (24, 27-31). The association of P. melaninogenica with clinical outcomes in CF 
or the pathogenesis of CF lung disease remains to be determined.  
In order to establish the role of P. melaninogenica in the pathogenesis of CF, we 
used quantitative aerobic and anaerobic culture to investigate whether the abundance 
and prevalence of P. melaninogenica in a cohort of CF patients at UNC-CH hospitals 
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was associated with clinical measurements of inflammation and lung function. Further, 
we assessed whether CF patients developed a P. melaninogenica associated adaptive 
immune response indicative of pathogenic exposure by measuring P. melaninogenica 
reactive antibody in serum. We found that although P. melaninogenica was present in 
the lungs of CF patients that bacterial isolation did not correlate with lung function 
(forced expiratory volume in 1 second, FEV1%) or acute inflammation (C-reactive 
protein, CRP). Additionally, we found a significance difference in P. melaninogenica 
reactive antibody response in pediatric CF patients and CF adults compared to disease 
controls.  
Material and Methods: 
Patient Selection and Design: All patients and volunteers included in this study were 
recruited under University of North Carolina Institutional Review Board approved 
protocols and patients or parents signed written consent, or assent for children old 
enough to read, for the primary study and for use of samples in this study. Serum was 
collected from 4 groups: Adults (n=28) and Children (n=33) with cystic fibrosis; disease 
control children (n=16) adult Healthy volunteers (n=21), and adults with mild asthma 
(n=9); SCCOR patients (n=11). For healthy adults only age and gender was collected. 
In patients with CF detailed clinical information was collected as part of the primary 
study from the patients’ chart. In the current investigation sex, age, FEV1% predicted, 
genotype and disease status (stable or exacerbation of CF). Spirometry in patients was 
measured at UNC clinics per ATS criteria. To allow for comparison across all age 
ranges results are expressed as % predicted [NHANES].  
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Bronchoscopy sample collection: Respiratory secretions: All bronchoalveolar lavage 
(BALF) samples were obtained as part of clinically indicated bronchoscopy at the UNC 
Children’s Hospital as previously described (32). Briefly, children received general 
anesthesia, and topical lidocaine was instilled at the level of the larynx and the tracheal 
bifurcation. To avoid aspiration or contamination of the specimen most CF patients had 
a laryngeal mask airway placed that allows advancing the bronchoscope protected from 
nasal or oral secretions to the level of the vocal cords. In non-CF patients exam of the 
upper airway was indicated and the bronchoscope was inserted through the left nare. In 
all cases suctioning through the bronchoscope was only performed below the vocal 
cords to avoid contamination. The location of bronchoalveolar lavage was at the 
discretion of the bronchoscopist, but was generally done in the lung segment most 
affected by disease, as evidenced by radiographic changes or by visual appearance at 
bronchoscopy. The bronchoscope was wedged in a bronchus and two to three aliquots 
of buffered normal saline solution were instilled and immediately aspirated through the 
bronchoscope. The total volume of instilled lavage fluid was 1-3 ml/kg body weight.  An 
aliquot of BALF for the research project was taken in a sterile manner.  The remainder 
of the BALF was sent to the hospital laboratory for cytology and cultures, which were 
ordered by the physician responsible for the patient.   
Blood collection: Venous blood was collected by standard phlebotomy, allowed to clot 
for 30 minutes and spun at 3500 x g for 5 minutes prior to storage at -80○ C. In children 
phlebotomy was typically combined with clinically indicated phlebotomy.  
Clinical Culture Procedures: Sputum and BALF samples were collected and placed 
under anaerobic conditions (5% C02, 10% H2, 85% N2 atmosphere, Coy Anaerobic 
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Chamber or AnaeroGen Pouch, Oxoid) within 30 minutes of collection. Sputum samples 
were plug-selected and the plugs treated with Sputolysin (Calbiochem) according to 
manufacturer’s instructions. 10-fold serial dilutions of the samples were prepared in 
25% strength Ringer’s Solution (Sigma) and 100µL aliquots from undiluted through 
1:105 were spread plated onto 3 sets of Anaerobic Blood Agar (Remel) and 1 set each 
of Kanamycin-vancomycin laked-blood agar (Remel), Chocolate agar with Bacitracin 
(Remel), and McKay agar. One set of Anaerobic Blood agar plates was incubated at 
37°C in ambient atmosphere for 2 days; one set of Anaerobic Blood agar, the Chocolate 
agar with Bacitracin, and the McKay agar were incubated at 37°C in 5% CO2 for 2 days; 
and the remaining Anaerobic Blood agar set and Kanamycin-vancomycin laked-blood 
agar were incubated for at 37°C anaerobically for 5-7days. Plates were examined and 
unique isolates were enumerated and subcultured. The threshold of bacterial detection 
was approximately 100 CFU/g. Fungal isolates and isolates recovered primarily from 
anaerobic plates which grew under 5% CO2 upon subculture were already collected 
through primary CO2 incubation and were no longer followed.  
Molecular Identification of bacterial species: Isolates were Gram-stained and their 
DNA extracted (Qiagen Human Blood and Tissue kit). The 16s ribosomal RNA gene of 
the isolates was PCR amplified using primers UniBac_0008F 
(AGAGTTTGATCMTGGCTCAG) and UniBac_1492R 
(TACGGYTACCTTGTTACGACTT) with MyTaq Red 2x mix (Bioline). Thermocycler 
Conditions: 95°C- 3min; 30x {95-20sec 50-20sec 72-90sec}; 72-10min. PCR cleanup 
was performed with ExoSAP-IT (Affymetrix). Sequencing was performed by Genewiz, 
Inc using primers UniBac_0008F, UniBac_0926R (CCGTCAATTCCTTTRAGTTT) and 
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UniBac_1492r. Sequence reads were assembled using Sequencher v4.8 (Gene Codes 
Corp.) using default settings. Assembled contigs were aligned and assigned taxonomic 
identification to the closest typed species using the SeqMatch tool of the Ribosomal 
Database Project (Michigan State University http://rdp.cme.msu.edu/).  
Bacteria growth and outer membrane preparation (OMP): P. melaninogenica and 
Porphyromonas gingivalis was plated from frozen stock onto Columbian Blood Agar 
then inoculated anaerobically in Anaerobic Broth (Becton Dickson Difco) at 37°C in Coy 
Anaerobic Chamber and grown until stationary phase. PAO1, a laboratory strain of P. 
aeruginosa, was plated from frozen stock on to Luria Broth (Becton Dickson) and was 
grown anaerobically in LB supplemented with 15mM KNO3 until stationary phase. 
Bacteria were then harvested by centrifugation 10,000 x g for 25 minutes at 4°C. 
Supernatant was removed then the pellet was resuspended in lysis buffer (50mM 
NaH2PO4, adjust to pH 7, 300mM NaCl) with 1mg/1ml lysozyme and incubated on ice 
for 30 minutes. The material was French Pressed twice.  Intact cells and cell debris 
were removed by centrifugation at 10,000 x g for 20 minutes at 4°C. Supernatant was 
centrifuged at 100,000 x g for 1 hour at 4°C. The pellet was then solubilized in 1% 
Sarkosyl and resuspended with a syringe 4 times and incubated for 30 minutes at room 
temperature with gentle shaking.  The Sarkosyl solution was subjected to centrifugation 
at 100,000 x g for 1 hour at 4°C. Supernatant was removed and pellet was resuspended 
pellet in 100 µl 1x PBS and was considered the outer membrane preparation. One large 
batch of each antigen was made and used for all ELISAs.  
Bacterial OMP ELISA: Total serum immunoglobulin G was measured according to 
manufacturer’s protocol (Jackson). Bacterial reactive IgG antibody titer was measured 
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as follows. Briefly, 96-well microtitration plates (Nunc Maxisorp) were coated and stored 
overnight at room temperature with 10 µg/ml bacterial OMP antigenic preparation in 
100mM Na2CO3 pH 9.6. Nonspecific binding sites were blocked for 1 hour with 1% 
bovine serum albumin and after washing with PBST 0.05%, patient sera in three well 
replicates were serially diluted five fold into 1% BSAT and incubated for one hour. 
Plates were then washed with PBST and incubated with Jackson goat anti-human IgG 
polyclonal antibody conjugated with Horseradish peroxidase (HRP) for 1 hour. 
Tetramethyl benzidine (TMB) was added to wells to detect HRP then the reaction was 
stopped by 2N H2SO4 and the color change was be measured by spectrophotometer at 
450nm minus plate background of 570nm.  Antiserum against P. melaninogenica OMP 
was raised in rabbits and obtained from Cocalico Biologicals, Inc., (Reamstown, PA) 
using standard procedures. Anti-OprF was used as a positive control for PAO1 to ELISA 
plate (laboratory stock). P. melaninogenica antibody developed against OMPs and P. 
aeruginosa OprF antibody was used on each plate to confirm equal amount of antigen 
coated per plate. A Jackson Normal Human serum (Jackson labs) was used on every 
plate to normalize plate to plate differences.  
CRP ELISA: As a clinical measurement of acute inflammation, C-reactive protein (CRP) 
was measured by an ELISA based method using CRP Ultra Sensitive (ILab™ 
Chemistry Systems) and analyzed by the automated biochemistry analyzer Ilab600 
(Instrumentation Laboratories Ltd). 
Absorption ELISA: Plates were coated with 10ug/ml of OMP preparation in 100mM 
Na2CO3 pH 9.6 overnight. Nonspecific binding sites were blocked for 15 minutes with 
1% bovine serum albumin then washed with PBST 0.05%. Pooled serum sample from 
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20 healthy and 20 CF adult patients were both diluted 1:1000 in BSA/PBS/Tw and 100µl 
was placed in triplicate into wells for 15 minutes at room temperature with gentle 
rocking. 100µl of the absorbed sera was then placed in fresh wells that had been coated 
with OMP preparation. The serum sample was absorbed at least 4 times. Aliquots from 
each absorbance in triplicate were collected and tested against each OMP preparation 
for changes in antibody level following the ELISA protocol above.  
Titer calculations and statistics: Linear regression models were used to determine 
correlation of total CFU/g and P. melaninogenica CFU/g and clinical measurements. 
Relative abundance was calculated imputing ones in those samples without a traceable 
CFU/g in order to complete linear regression analysis. To compare absorbance 
readings in supplementary data ANOVA Tukey's Multiple Comparison Test and the 4th 
absorbance was graphed using Graphpad Prism software. Mann-Whitney non 
parametric two tailed tests were used to compare IgG titers.  P. melaninogenica, P. 
aeruginosa and P. gingivalis reactive antibody titers were calculated by subtracting 
background from absorbance values then taking the Log of absorbance greater than 
OD 0.1 minus the Log of the absorbance less than OD 0.1.  The results are expressed 
as mean values plus/minus standard deviation, and statistical significance (P < 0.05) 
using Graphpad Prism software.   
 
Results: 
Clinical Characteristics of UNC Cohort 
Demographic and clinical characteristics of the study subjects are summarized (Table 
1). BALF was collected from 29 children ranging in age from 1 to 17 years. 
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Spontaneous expectorated sputum was collected from 28 CF adults, ranging from 18 to 
33 years of age, and four stable CF children from 12 to 16 years old. Control subjects 
for this study included asthmatic children (n=16), asthmatic and smoking adults (n=20) 
and healthy non-smoking adults (n=21) that ranged from 1 to 57 years old. The majority 
of the CF patients were female (57%) and had delta F508 genotype (86%).  
 
The CF microbiota in Adults and Children    
 Using culture based methods to examine microbes in the CF lung, we found that 
Staphylococcus, Streptococcus and Haemophilus were the most abundant genera in 
pediatric BALF and sputum samples (Figure1A, Figure1B). From adult sputum samples, 
Staphylococcus, Pseudomonas and Streptococcus were the most abundant genera 
(Figure 1C). Among strict anaerobes cultured Prevotella spp. were the most abundant 
genus cultured from CF adult sputa, pediatric CF sputa and BALF.   
 
P. melaninogenica is a frequent strict anaerobe in CF 
In BALF cultures from pediatric patients, P. melaninogenica was the most 
abundant species found in exacerbating patients and was highly abundant in stable 
patients, second only to S. aureus and Streptococcus mitis (Figure 2A).  P. 
melaninogenica was cultured from all sputa collected from stable CF pediatric patients 
(Figure 2B).  The most prevalent species in adult stable patients and one of the most 
prevalent species in adult exacerbations is P. melaninogenica (Figure 2C). P. 
aeruginosa and Streptococcus salivarius both were cultured frequently from stable adult 
patients. P. aeruginosa and S. aureus were also recovered at high levels from adult 
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exacerbations (Figure 2C).  P. melaninogenica was not only a frequent colonizer of CF 
patients, but was also isolated in high numbers (as high as 1.8x108 CFU/g in one adult 
stable CF sputum and 8.0x108 CFU/g in one child stable CF sputum) (Figure 3).   
 
Clinical measurements:  
To determine whether bacterial lung colonization correlated with clinical 
parameters, we compared total amount of cultivable bacteria per gram of sample 
(CFU/g) with pulmonary function (FEV1%) and C-reactive protein (CRP).  The total 
amount of bacteria cultivated did not correlate with clinical measurements of the patient 
population (data not shown).  In our cohort, consistent with previous studies (7, 33, 34), 
there was a significant positive correlation between CF patient age and FEV1% (n=35, 
p=0.0115), CRP (n=61, p=0.0220) and total CFU/g (n=61, p=0.0167), not seen in non-
CF controls (Figure 4A).  We found that adult CF patients (n=28) had significantly higher 
CRP values than non-CF disease controls (n=20, p<0.0001) and healthy individuals 
(n=21, p<0.0001) (Figure 4B). Additionally, stable CF adults (n=16) had significantly 
lower CRP than exacerbating CF adults (n=12, p=0.0005). In children, we detected no 
significant difference between CF and non-CF diseased controls and between stable 
and exacerbating CF children (Figure 4C).   
Given the high frequency of P. melaninogenica in our study (19/28 adults, 19/33 
children), we investigated the effect of P. melaninogenica culture status on clinical 
parameters CRP and FEV1%.  There was no significant correlation of abundance or 
frequency of P. melaninogenica in adult CF patients with the FEV1% and CRP 
measurements (Data not shown).  In summary, P. melaninogenica is the most prevalent 
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strict anaerobic species in adult sputum samples and child BALF and sputum, although 
P. melaninogenica abundance or positive culture appears to not significantly correlate 
with clinical measurements.  
 
Adaptive immune response to P. melaninogenica 
To determine whether isolation of P. melaninogenica was associated with an 
adaptive immune response, patient sera were tested by ELISA for reactivity with an 
outer membrane preparation of P. melaninogenica ATCC 25845.  In order to assess the 
specificity of the outer membrane ELISA, we tested pooled sera from 20 adult CF 
patients and 20 healthy adults.  Pooled sera were absorbed against wells coated with P. 
melaninogenica, P. aeruginosa or empty wells.  As expected there was a significant 
decrease in P. melaninogenica reactive antibody level (p<0.05) when P. 
melaninogenica antibodies were removed from diluted CF and healthy sera (Figure 5A).  
As a Gram-negative control to show ELISA specificity (and a bacterium that is seen in 
low numbers in CF patients), we measured P. gingivalis reactive antibody level and 
found that when either P. melaninogenica or P. aeruginosa antibodies were removed 
there was not a reduction in P. gingivalis reactive antibody levels in CF or healthy adult 
sera (Figure 5B).  In addition the removal of P. melaninogenica antibodies did not cause 
a significant reduction in CF and healthy total IgG level (Figure 5C).  In summary, this 
outer membrane ELISA does represent a method of assessing P. melaninogenica 
reactive antibody response in patient sera. 
To investigate individual serum P. melaninogenica reactive antibody titer, we 
tested individual patient sera by a P. melaninogenica OMP ELISA.  There was a 
52 
significant increase in P. melaninogenica reactive antibody titers in CF adults (n=28) 
compared with non-CF individuals (n=20, p<0.0001) and healthy volunteers (n=21, p 
<0.0001) (Figure 6A). Investigating exacerbation and stable CF patients there was no 
significant difference in P. melaninogenica reactive antibody titers (data not shown). 
There was no significant difference in total IgG in the adult CF, non-CF and healthy 
adults (data not shown).   To further investigate reactive antibody titers, pediatric 
patients with CF and non-CF individuals’ response was measured. There was a 
significant difference in P. melaninogenica reactive antibody titers in CF children (n=33) 
and non-CF individuals (n= 16, p=0.0196) (Figure 6B). There was no difference in P. 
melaninogenica reactive antibody titers in stable CF verse exacerbation patients or in 
total IgG in CF children and non-CF individuals (data not shown).  P. aeruginosa OMP 
ELISAs were also completed on adult and pediatric CF and non CF individuals and 
mirrored the results of P. melaninogenica reactive antibody response (data not shown).  
Because of the specific anaerobic and nutritional environmental requirements of 
P. melaninogenica, we hypothesized that CF adults would have more opportunity for 
colonization by P. melaninogenica and thus would have a higher immune response 
against OMPs of P. melaninogenica than children. Indeed, CF adults (n=28) have a 
significantly higher P. melaninogenica titer compared to CF children (n=33, p=0.0002) 
(Figure 6C). No significant difference was observed in P. melaninogenica reactive 
antibody titer in non-CF adults compared to non-CF children (Figure 6D) or total IgG in 
the same groups (data not shown).   
While P. melaninogenica is prevalent in our study, P. aeruginosa is traditionally 
considered the classic CF pathogen so we investigated P. aeruginosa reactive antibody 
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response and P. melaninogenica reactive antibody response. Comparing bacterial 
reactive antibody titer reveals that there is a correlation of P. melaninogenica and P. 
aeruginosa titer in CF adults and children (Figure 7).   
Discussion 
Bacterial cultivation represented as total CFU/g has been compared to clinical 
measurements previously (4, 6).  The weak correlation of these components earlier has 
shed light on the complex nature CF lung disease. Detection threshold and culturing 
limits, along with the cross-sectional nature of this study presents a limited picture of the 
CF microbiome which plays a role in this inconsistent result. As expected, there was a 
correlation between patient age and a time dependent development of microflora which 
has been seen in other studies (11).  
The clinical significance of anaerobes, specifically P. melaninogenica, remains 
uncertain. In this study, P. melaninogenica is the most frequently cultured strict 
anaerobe in children and adults with CF relative to other species.  This has been 
corroborated by previous studies investigating the CF microbiome (13, 15, 17, 19, 23). 
Two studies of explanted lung specimens have still suggested that oral anaerobe 
cultivation in CF samples due to ‘oral contaminants’ (35, 36). In our study, P. 
melaninogenica could be cultured from mouthwash samples, but it did not occur at the 
same abundance as was seen in sputum samples (data not shown).  Here, we found 
that frequency and abundance of P. melaninogenica does not correlate with FEV1% in 
CF children or adults. This study is the first paper to follow up the cultivation of a strict 
anaerobe and determine P. melaninogenica effect on FEV1% and CRP in the CF 
population.  
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In addition to culturing bacteria, host acquired immune response is indicative of 
bacterial exposure. Serum antibody titers are frequently used as a readout of bacterial 
infection (37, 38). IgG antibody production is the most common antibody used because 
of its abundance in the blood and its specificity to repeat pathogen exposure.   In adult 
CF populations, a high level of P. aeruginosa specific IgG antibody has been used for 
diagnostic purposes (39, 40).  Serological diagnosis can be made 6-12 months before 
culturing the bacteria (38). Consistent with this finding, a high level of P. aeruginosa 
specific IgG antibodies correlate with negative clinical outcome reflecting bacterial 
colonization (40). 
In this study, both CF children and adults had an increased P. melaninogenica 
IgG titer compared to controls. Additionally P. melaninogenica IgG titer is significantly 
increased in CF adults compared with CF children. Diagnostic serological testing in 
periodontal disease and CF has been a valuable tool for treatment regimens (40, 41).  
Recently, in a study investigating the contribution of another Prevotella species, 
Prevotella intermedia, the authors showed an increased P. intermedia antibody titer in 
teenagers (median age 15) compared with healthy adults (median age 25 years) (15).  
Our results show that P. melaninogenica IgG titer also is increased in adult patients 
compared to children. This finding is consistent with older CF patients having an 
increased likelihood of encountering Prevotella spp., or other bacteria, as they age.  
In summary, P. melaninogenica is an abundant member of the CF airway 
microbiota. Our study supports a CF specific adaptive immune response to P. 
melaninogenica antigens though no clinical measurement correlation with culturing of P. 





Cystic fibrosis (n=61) Non-CF (n=36) Healthy (n=21) 
Demographics 
 
Child (n=33) Adult (n=28) Child (n=16) Adult (n=20) Adult (n=21) 
 
Age:  Median (Range) 5(1-17) 22(18-33) 5.5(1-11) 27 (19-44) 24(20-57) 
 
Gender: Male/Female 11/22 15/13 7/9 13/7 14/9 
 
Genotype: (Delta F508/Other) 28/5 25/3 n/a n/a n/a 
Disease State 
 
          
 
Disease Status: Exacerbation/Stable 20/13 12/16 n/a n/a n/a 
 
FEV1% predicted: Mean (Median) Not reliable 57.7 (60.5)# n/a n/a n/a 
 
CRP µg/ml: Mean 1.38E+04 2.47E+05 2.43E+04 2.73E+04 3.82E+04 
       
 
# 4 not recorded 
     
 Table 2.1- Characteristics of UNC study cohort.  
CF= cystic fibrosis. FEV1%= forced expiratory volume in one second compared to patients of similar characteristics 





Figure 2.1.  Microbiome Composition of Sputum and BALF Samples. Abundance of 
genera in A) Pediatric BALF samples B) Pediatric Sputum samples. C) Microbiome 
Composition of Adult sputum samples Data are percent of total CFU/g recovered for 
each genus. Total Log10 CFU/g recovered from each specimen is listed at the top of 






































Figure 2.2. Most frequently cultured species in CF samples. A) Pediatric BALF samples 






















Figure 2.3. P. melaninogenica CFU/g in CF patient samples. Vertical Scatter Plot using 
mean, graphed in Graphpad Prism. 
Grayed bars= sputum 












Figure 2.4. Comparisons of age to clinical measurements. A) Correlation of CF patient 
age to FEV1% (n=35, r
2=0.1785, p=0.0115), CRP (n=61, r2=0.08576, p=0.0220) and 
total CFU/g (n=61, r2=0.0933, p=0.0167). Values were derived from linear regression 
model using Graphpad Prism.  B) Significance of CRP values in adult patient groupings 
(p> 0.001). C) CRP levels in pediatric CF patients and non CF individuals. Values were 


































Figure 2.5: Absorbance experiments testing specificity of P. melaninogenica ELISA A) 
P. melaninogenica levels when absorbing sera against P. aeruginosa antigen or empty 
wells. B) P. gingivalis levels when absorbing against P. aeruginosa antigen or P. 
melaninogenica antigen or empty wells. C) Total IgG measurements of absorbed sera. 
Each measurement was done in triplicate and averaged. Shown is the fourth absorption 
event. ANOVA- Tukey's Multiple Comparison Test was used and analyzed in Graphpad 
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Figure 2.6 P. melaninogenica reactive antibody titer in CF Adults, CF children and 
controls A) P. melaninogenica titer measured in individual adult sera (p<0.0001). B) P. 
melaninogenica titer measured in CF children compared to Non CF individuals 
(p=0.0196). C) P. melaninogenica titers in adult and pediatric CF patients (p= 0.0002). 
D) P. melaninogenica titers in adult and pediatric individuals (p=0.4540). Box and 
Whisker Plot was graphed by Graphpad Prism using minimum, maximum, media and 























Figure 2.7: P. melaninogenica and P. aeruginosa reactive antibody comparisons A) P. 
melaninogenica IgG and P. aeruginosa IgG titer correlation in Adult CF patients. 
r2=0.2038, p=0.0159. B) P. melaninogenica and P. aeruginosa IgG titer correlation in 
CF children. r2=0.1284, p=0.0406. Graphs were derived from linear regression model 
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 Chapter 3 
 
Structure and innate immune response to lipopolysaccharide lipid A 
of Prevotella melaninogenica 
 
Abstract:  
Prevotella melaninogenica, regarded as a commensal oral bacterium, is 
frequently isolated from extra-oral polymicrobial infections, including the airways of 
individuals with the genetic disease cystic fibrosis (CF).  The CF airway environment is 
known to support a complex polymicrobial community that persists and evolves over 
time.  Aerobic bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa 
are considered the primary pathogens in CF; consequently, little is known about the 
contribution of anaerobic bacteria such as P. melaninogenica in CF disease 
pathogenesis. Lipopolysaccharide (LPS), the primary constituent of the outer membrane 
of Gram-negative bacteria, has the potential to be an important proinflammatory 
mediator. We characterized the lipid A structure of P. melaninogenica and determined 
whether P. melaninogenica LPS stimulated an inflammatory response in the human 
monocytic cell line THP1. We found that lipid A of P. melaninogenica is highly 
heterogeneous under in vitro growth conditions, and is composed of 
monophosphorylated and diphosphorylated forms that are penta-acylated with 
unusually long chain fatty acids. Consistent with the presence of long chain fatty acids 
the LPS of P. melaninogenica LPS was more than 1000-fold less stimulatory than that 
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of Pseudomonas aeruginosa. Further, P. melaninogenica LPS activity was not mediated 
by Toll-like receptor 4 (TLR4), suggesting that residual activity was due to lipoprotein 
contamination. Our results indicate that P. melaninogenica produces a highly unusual 
non-stimulatory LPS and that it is unlikely to contribute to the unrelenting inflammatory 
response associated with chronic CF airway infection.  
Introduction: 
Bacterial lipopolysaccharide (LPS) comprises the outer layer of the outer 
membrane of Gram-negative bacteria.  LPS has three biochemically distinct regions: 
lipid A, core polysaccharide and O-antigen (1).  Lipid A, traditionally considered the 
most toxic portion, constitutes the hydrophobic component of LPS and is made up of 
long chain fatty acids covalently attached to a sugar derivative, glucosamine. The core 
polysaccharide, which is attached to lipid A, is composed of an inner core of short 
oligosaccharide and 2-keto-3-deoxyoctonoic acid (KDO), and an outer core that is 
composed of phosphates, amino acids and sugars.  Attached to the core is the O-
antigen, the most variable part of the LPS, which is made up of repeating saccharide 
subunits.   
Bacterial LPS aids in colonization and survival of bacteria inside the host. LPS is 
vital to bacterial structure and outer membrane integrity and is involved in bacterial 
pathogenesis by acting as a physical/permeability barrier to protect bacteria from host 
immune defenses and by aiding in the attachment to host cells (2).  The addition of 
sialic acid to the core or O-antigen portion of LPS can aid in bacterial immune evasion 
by mimicking host cell surface molecules, thus preventing host immune detection and 
clearance by antibody opsonization (3).  
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The lipid A component of LPS also serves as a microbe-associated molecular 
pattern (MAMP) that is specifically recognized by host cells through the Toll-like 
receptor 4 (TLR4) complex (4).   In the host, bacterial LPS is recognized by LPS binding 
protein (LBP). The LPS-LBP complex can subsequently bind CD14 and activate the 
TLR4-MD-2 receptor complex.  Binding of LPS to TLR4 initiates a signaling cascade 
that ultimately activates NFĸB transcription. Upon translocation to the nucleus, NFĸB 
activates the transcription of proinflammatory cytokine genes, such as IL-8, as well as 
other responses including complement activation and reactive oxygen release from 
macrophages and neutrophils (5).  The host response induced by bacterial LPS plays a 
role in the pathogenesis of many human diseases including cystic fibrosis (CF) (6).  
CF is the most common genetic disorder affecting Caucasians of European 
descent. In CF, mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene lead to dysregulation of chloride ion transportation across the apical 
surface of epithelial cells. The resulting ion imbalance causes mucus dehydration and 
formation of thick luminal mucus plugs (7). Mucus plugs are proposed to provide an 
ideal niche that protects bacteria from antimicrobial agents and antibody mediated host 
responses.  Bronchoalveolar lavage fluid (BALF) collected from CF patients, shows 
increased neutrophil counts, elevated concentrations of proinflammatory cytokines (e.g. 
IL-8, IL-1β, TNFα, IL-6), and inflammatory markers such as C-reactive protein (CRP) 
compared to BALF from individuals with non-CF respiratory disease or healthy 
individuals (8-10). Bacterial infection within the thickened luminal mucus of CF airways 
leads to unrelenting and non-productive inflammation, which contributes to progressive 
lung damage, and ultimately respiratory failure.   
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In individuals with CF, polymicrobial colonization occurs as early as two months 
of age (11). In the context of this underlying bacterial community, typical CF pathogens 
appear in a succession; with Staphylococcus aureus and Haemophilus influenzae 
dominating early in life, followed by chronic colonization by Pseudomonas aeruginosa 
and members of the Burkholderia cepacia complex (11, 12). Unbiased molecular 
detection methods, based on bacterial 16S rRNA gene sequencing or phylogenetic 
microarrays, have shed new light on the complexity of the CF microbiome and implicate 
anaerobic bacterial species as dominant members of the CF airway microbiota (11, 13-
22). These findings have been confirmed by parallel anaerobic culture based studies 
(23-33). Among the anaerobic species, Prevotella melaninogenica has emerged as a 
frequent and abundant member of the CF airway microbiota (14, 19-21, 23, 29, 30). 
P. melaninogenica is a black pigmented, Gram-negative bacterium and a 
member of the human oral flora (34). P. melaninogenica is found in extra-oral abscess 
sites such as vertebral osteomyelitis, pyomyositis, peritonsillar abscesses and vaginal 
mesh infections (35-39).  P. melaninogenica has the capacity to produce a range of 
potential virulence factors such as hemolysin, β-lactamases, fibrinolysin, IgA protease, 
IgG protease and lipase (40-45).   Additionally, P. melaninogenica has been described 
as a potential pathogen because of its presence in polymicrobial diseases such as brain 
abscesses, pleuropulmonary infections, endocarditis, illicit drug injection sites, intra-
abdominal infections, wound infections, necrotizing fasciitis, pyogenic infections, 
decubitus and diabetic ulcers in addition to CF (26, 36, 42, 46-51). 
In the context of CF airway disease, the potential role of P. melaninogenica in 
inflammation has not been examined. In particular, the structure and stimulatory 
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properties of P. melaninogenica LPS, a major proinflammatory mediator of Gram-
negative infection, have not been characterized. The goal of this study was to determine 
the P. melaninogenica lipid A structure and its inflammatory potential, in order to better 
understand its contribution to the pathogenesis of CF airway infection and disease 
pathogenesis. We found that there are two dominant forms of P. melaninogenica lipid A 
composed of monophosphorylated and diphosphorylated forms with five unusually long 
(C15-C17) acylated chains. Additionally, P. melaninogenica LPS was found to be 
exceptionally non-stimulatory with regard to IL-8 and IL-1β activation compared to LPS 
from P. aeruginosa in THP1 cells.  
Materials and Methods:  
Bacterial strains and growth conditions: P. melaninogenica ATCC 25845 was cultured 
from frozen stock onto Columbian Blood agar plates (Thermo Scientific) for three days. 
P. melaninogenica was then grown in prereduced Tryptic Soy Broth (Becton Dickinson) 
supplemented with 5 µg/ml menadione (Sigma) and 5 µg/ml (7.6 µM) heme (anaerobic 
Tryptic Soy Broth, ATSB) with shaking overnight at 37°C in a Coy anaerobic chamber 
(52).  20 milliliters of overnight culture was used to inoculate 1L of ATSB and grown for 
three days. Bacteria were then centrifuged at 10,000xg for 25 minutes at 4°C and the 
pellet was frozen at -20°C.   P. aeruginosa strain PAK was plated on LB and grown in 
N-minimal media supplemented with 38 mM glycerol, 0.1% casamino acids and 8 µM 
MgCl2, a condition that promotes production of lipid A with modifications typical of CF 
clinical isolates (53).  
LPS and lipid A isolation and purification. LPS was extracted by the hot/phenol/water 
method (54). Freeze-dried bacteria were resuspended in endotoxin-free water at a 
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concentration of 10 mg/ml.  12.5 milliliters of 90% phenol was added and the resultant 
mixture was vortexed and incubated in a hybridization oven at 65°C.  The mixture was 
cooled on ice and centrifuged at 10,000 rpm at room temperature for 30 minutes.  The 
aqueous phase was collected and an equal volume of endotoxin-free water was added 
to the organic phase.  The sample was treated as above and aqueous phases were 
combined and dialyzed against Milli-Q purified water to remove residual phenol and 
then freeze-dried. The resultant pellet was resuspended at a concentration of 10 mg/ml 
in endotoxin-free water and treated with DNase at 100 µg/ml and RNase A at 25 µg/ml 
and incubated at 37°C for 1 hour in a water bath.  Proteinase K was added and 
incubated for 1 hour in a 37°C water bath.  The solution was extracted with an equal 
volume of water-saturated phenol.  The aqueous phase was collected, dialyzed against 
Milli-Q purified water and freeze-dried as above. The LPS was further purified by adding 
a 2/1 mixture of chloroform/methanol to remove membrane phospholipids using the 
Folch procedure (55) and further purified by an additional water-saturated phenol 
extraction and 75% ethanol precipitation using the Vogel procedure (56) to remove 
lipoproteins. 1 mg of purified LPS was converted to lipid A by mild-acid hydrolysis (57), 
which was used for High-Order MS analysis. 
Rapid microextraction Lipid A isolation from whole cells. The P. melaninogenica Lipid A 
that was analyzed by MALDI-TOF mass spectrometry was prepared using a published 
isolation method (58). Briefly, approximately 10 mg of lyophilized material derived from 
an overnight culture of each strain was resuspended in 400 μl of isobutyric acid and 1 M 
ammonium hydroxide (5:3 vol/vol) and incubated at 100°C for 1 h. After cooling, 
individual samples were centrifuged for 15 min at 2,000 x g, and supernatants were 
78 
collected and diluted 1:1 (vol/vol) with endotoxin-free water. The samples were 
subsequently frozen and lyophilized overnight. The resultant powered material was then 
washed twice with 1 ml of methanol and the insoluble lipid A was extracted in 200 μl of 
a mixture of chloroform, methanol, and water (3:1:0.25 [vol/vol/vol]). One microliter of 
this extract was then spotted onto a MALDI plate followed by 1 μl of norharmane matrix 
(Sigma) and air-dried.  
Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI 
TOF MS): Lipid A was analyzed in the negative ion mode on an AutoFlex Speed MALDI 
TOF mass spectrometer (Bruker Daltonics, Bremen, Germany). Samples were 
dissolved in 10 µL of a mixture of n-harmane (20 mg/mL) in chloroform/methanol/water 
4:4:1 (vol/vol/vol), and 0.5 µL of sample was spotted directly onto the MALDI target 
plate. Data was acquired in reflectron mode with a Smartbeam laser with 1 kHz 
repetition rate and up to 4000 shots were accumulated for each spectrum. Instrument 
calibration and all other tuning parameters were optimized using Agilent Tuning mix 
(Agilent Technologies, Foster City, CA).  Data was acquired and processed using Data 
Analysis (Bruker Daltonics, Billerica, MA). 
Matrix-Assisted Laser Desorption Ionization Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometry (ESI FT-ICR MS): Lipid A was analyzed by MALDI in 
the negative ion mode on a 12-Tesla FT-ICR mass spectrometer (Bruker Daltonics, 
Bremen, Germany). Samples were dissolved in 10 µL of a mixture of n-harmane (20 
mg/mL) in chloroform/methanol/water 4:4:1 (vol/vol/vol), and 0.5 µL of sample was 
spotted directly onto the MALDI target plate. Data was acquired with a Smartbeam laser 
with 2 kHz repetition rate and up to 3000 shots were accumulated for each spectrum. 
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Instrument calibration and tuning parameters were optimized using the recommended 
Bruker calibration standard mixture (Bruker Daltonics, Bremen, Germany) in negative 
ion mode. Tandem mass spectrometry experiments involved isolation and collision 
induced fragmentation of the precursor ion in the front end quadruple. Precursor 
isolation was set to 5 Da and fragmentation energy was adjusted accordingly to 
maximize observation of product ions. Data was acquired and processed using Data 
Analysis (Bruker Daltonics, Billerica, MA).  
Cell culture:  THP1 XBlue cells (Invivogen, San Diego, CA) were grown according to 
American Type Culture Collection (ATCC) instructions in RPMI-1640 medium with 
Zeocin (100 µg/ml) in 5% CO2. For LPS challenge studies, 5 x10
5 THP1 XBlue cells 
contained in 500 µl were seeded into 24 well plates, incubated for 30 minutes and 
challenged for 24 hours with LPS. LPS was diluted in endotoxin free H2O. E. coli LPS 
(Sigma) and Pam3CSK4 (Invivogen) were used as controls for TLR neutralizing 
experiments at 50 ng/ml and 10 ng/ml, respectively. TLR2 and TLR4 neutralization 
experiments were conducted as previously published (59, 60). Specifically, 1x105 THP1 
cells contained in 100 µl media were plated and 5 µg/ml of anti-TLR2 or anti-TLR4 
antibody (TLR2: Anti-human (CD282) Purified TL2.1; TLR4: Anti-Human CD284 
(TLR4)); eBioscience) or isotype IgG2a control (Mouse IgG2a K Isotype Control, 
eBioscience) were added to cell culture, swirled and incubated for two hours at 37°C 
before LPS was applied and incubated for 24 hrs. 
ELISAs:  Total IL-1β and IL-8 were measured by enzyme-linked immunosorbent assay 
(ELISA) in 96 well polystyrene high binding plates (Corning Costar) according to 
manufacturer’s instructions (R&D). For NFĸB activation measurements, cells were 
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maintained with Zeocin and supernatant was collected and frozen at -20°C. 20 µls of 
cell supernatant was added to 200 ul of QuantiBlue (Invivogen) and incubated for 1 to 2 
hours and read at 650nm. 
Statistics: Data were analyzed by analysis of variance (ANOVA) and the Tukey multiple-
comparison test using the Graphpad program (Graphpad Software, San Diego, Calif.). 
Statistical differences were considered significant for P values of less than 0.05. All 
reported experiments were performed at least twice in triplicate and each graph 
represents standard deviation of averages.   
Results: 
Characterization of P. melaninogenica lipid A structure.  
The lipid A structure of P. melaninogenica has not been previously described. To 
determine lipid A structure, the typed P. melaninogenica strain ATCC 25845 was grown 
in ATSB (7.6uM heme) and lipid A was purified by Caroff method and analyzed by 
negative matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass 
spectrometry (MS) and Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass 
spectrometry.  
The negative ion mode MALDI TOF mass spectrum of lipid A isolated from P. 
melaninogenica LPS is shown in Figure 1A and 1B. The most abundant ions observed 
corresponded to two different ion series at m/z values ranging from 1646-1702 and from 
1726-1796. These ion series corresponded to singly deprotonated lipid A structures that 
contained one phosphate group (monophosphoryl) or two phosphates (diphosphoryl) 
and five acyl chains (penta-acylated), respectively. Within the ion series, each ion peak 
differed by 14 Da, which corresponded to an addition/subtraction of a methyl group. 
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Initial structure characterization using precursor ion m/z values were supported by 
elemental composition based on accurate mass measurements.  
Tandem mass spectrometric experiments on penta-acylated lipid A isolated from 
P. melaninogenica LPS were carried out to confirm the location of the five fatty acids. 
The most abundant monophosphoryl m/z value, 1674, was selected for full acyl chain 
configuration assignment (Figure 1B). Initial characterization based on elemental 
composition from accurate mass measurements of the mono-phosphoryl penta-acylated 
lipid A anion, m/z 1674, revealed the composition of the five fatty acids comprised of 
four primary fatty acids [two 3-hydroxypalmitic acid (C16(3-OH)) acyl chains, one 3-
hydroxy-methyl-tetradecanoic acid (C15(3-OH)(isomethyl)), and one 3-hydroxy-methyl-
hexadecanoic acid (C17(3-OH)(isomethyl)) acyl chains] and one secondary fatty acid 
[palmitic acid (C16) acyl chain].  
In order to determine the positioning of the five fatty acids, we conducted tandem 
mass spectrometric experiments aimed at highlighting diagnostic cross-ring and 
glycosidic cleaveage product ions that provided decisive evidence for pinpointing acyl 
chain positions (Figure 1B). The penta-acylated lipid A structure was determined to 
have the following configuration: the C-2 position contained a primary amide-linked 
C16(3-OH), the C-3 position contained a primary ester-linked C16(3-OH), the C-2' 
position contained a primary amide-linked C17(3-OH)(isomethyl) and a secondary 
ester-linked C16, and the C-3' position contained a primary ester-linked C15(3-
OH)(isomethyl). The acyl chain configuration as outlined above held true for 
diphosphoryl penta-acylated lipid A extracted from P. melaninogenica (Figure 1A).  
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 IL-8 and IL-1β response to P. melaninogenica LPS.  
To test the ability of P. melaninogenica LPS to stimulate the host inflammatory 
response, we exposed the THP1 human monocytic cell line to purified LPS and 
evaluated production of IL-1β, a key acute phase inflammatory cytokine, and IL-8, a 
neutrophil chemokine.  LPS from P. melaninogenica stimulated low levels of IL-8 
(approximately 50 pg/ml), but no detectible level of IL-1β (Figure 2A and 2B). In 
contrast, LPS from P. aeruginosa, a traditional pathogen associated with CF, stimulated 
IL-8 production 1000 fold more than P. melaninogenica LPS. 
 
P. melaninogenica LPS is not a TLR4 agonist.  
 To determine whether the weak cytokine response to P. melaninogenica LPS 
was mediated through a TLR4-dependent pathway, we used TLR neutralizing 
antibodies to block LPS signaling. E. coli LPS was used as a traditional TLR4 agonist to 
test the effectiveness of the blocking of TLR4 by antibodies. E. coli LPS signal was 
ablated with the addition of TLR4 neutralizing antibody. In our studies, TLR4 
neutralizing antibody had no effect on P. melaninogenica LPS dependent NFĸB 
activation or IL-8 production in THP1 cells (Figure 3). As expected the isotype mAb 
control did not reduce P. melaninogenica NFĸB activation or IL-8 secretion.  We also 
tested the ability of P. melaninogenica to signal through TLR2 because of contrasting 
studies in a closely related bacterium Porphyromonas gingivalis. Pam3CSK4, a 
lipoprotein, is a traditional TLR2 agonist and its effect was successfully reduced with the 
addition of TLR2 neutralizing antibody. The TLR2 neutralizing antibody reduced P. 
melaninogenica LPS dependent NFĸB activation and IL-8 production three fold each. 
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The isotype mAb control did not reduce P. melaninogenica NFĸB activation or IL-8 
production (Figure 4).   
Discussion  
P. melaninogenica, a prominent anaerobic member of the CF microbiome, has 
an uncharacterized lipid A structure and unknown LPS dependent inflammatory effect 
that could contribute to CF pathogenesis.  This study represents the first investigation 
into lipid A structure and inflammatory response to P. melaninogenica LPS.   
Mass spectra of P. melaninogenica lipid A displayed penta-acylated 
diphosphorylated and monophosphorylated form (m/z 1754 and 1674, Figure 1). In 
studying the structure of lipid A there are four main areas of potential variation:  the 
number of phosphates attached to the glucosamine backbone, the number and length 
of acyl chains and whether the acyl chains are branched (61).  Contrasting E. coli lipid A 
structure to P. melaninogenica reveals key differences in phosphate composition, acyl 
chain number and length. E. coli lipid A traditionally is composed of 6 acyl chains with 
lengths ranging from 12 to 14 carbons and two phosphates attached to the glucosamine 
backbone (62). These key differences could explain the striking difference in IL-8 
production and TLR signaling between the two complete LPS structures. Lipid A 
molecules that have two phosphates attached to the glucosamine background are 
known to be more potent activators of TLR4 than lipid A molecules with a single 
phosphate or no phosphate (62). Additionally, lipid A containing  5 or 7 acyl chains is 
100 fold less active compared to structures with 6 acyl chains (63). P. melaninogenica 
lipid A moiety displays a similar structure and acylation pattern to P. gingivalis, an oral 
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pathogen associated with periodontitis (62, 64). P. gingivalis lipid A is penta-acylated 
and monophosphorylated and has a less potent cytokine profile than E. coli (62, 65). 
In our experiments with purified LPS, we established that P. melaninogenica did 
not initiate high levels of IL-1β and IL-8 inflammatory cytokine production or NFĸB 
activation in THP1 cells; even lower than P. gingivalis in similar conditions (66, 67). The 
low stimulatory effect of P. melaninogenica is confirmed by a past report of low IL-1α 
and TNFα secretion induced by P. melaninogenica supernatants on human monocytes 
and human gingival cells compared with Salmonella typhimurium LPS and 
Fusobacterium nucleatum lysate (68).  In the oral cavity, where P. melaninogenica is 
considered a commensal, the community of oral bacteria contributes to periodontal 
health by stimulating low levels of IL-8 to induce the chemotaxis of neutrophils into the 
gingivalis crevice where they patrol for bacterial pathogens (69). In other parts of the 
body, low level stimulation by commensal bacteria aids in the development and 
maintenance of the immune innate system as seen in experiments with germ-free mice 
(70).   In CF lung infections though, the additional low-level stimulation could add to the 
overall excessive inflammatory phenotype displayed which leads in the destruction of 
lung tissue and pulmonary dysfunction. P. melaninogenica could minimally contribute to 
increase the inflammation of the CF through increased IL-8 cytokine response. 
  To investigate the mechanism of THP1 IL-8 production in response to P. 
melaninogenica, TLR signaling pathways were investigated to determine if P. 
melaninogenica was signaling through a traditional TLR pathway. Experiments blocking 
TLR2 or TLR4 with neutralizing antibodies were done to elucidate TLR signaling 
pathways of P. melaninogenica LPS.  Blocking TLR2, in contrast to blocking the 
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traditional TLR4 pathway, resulted in a significant decrease in P. melaninogenica LPS 
dependent NFĸB activation and IL-8 production.  Antibody blocking experiments 
demonstrated that the low-level proinflammatory activity associated with P. 
melaninogenica LPS is detected through a TLR4 independent pathway.  This result 
substantiates a continuing controversy in the field P. gingivalis.  
The LPS dependent TLR response to P. gingivalis is unclear because of reports 
outlining both TLR2 and TLR4 LPS dependent pathways. Zhang et al., demonstrates in 
THP-1 cells that TLR2 antibodies block the production of significant amounts of IL-1β, 
TNFα and IL-6 cytokines (67).  This study though also reports robust P. gingivalis LPS 
cytokine response above that of E. coli, contradicting previous studies comparing the 
two (53, 71).  This could be because of lipoprotein contamination leading to TLR2 
agonism and high levels of cytokine response. Exploring lipid A structure and 
environmental cues, Coats et al. shows a variable TLR dependent response depending 
on the amount of heme in the environment (52).  Specific lipid A phosphatases are 
regulated by heme concentration and are responsible for changes in lipid A structure 
leading to variable TLR4  response either acting as an agonist in low heme (1 mg/ml) or 
an antagonist in high heme (10 µg/ml) (52). 
Further experiments will be done with additional P. melaninogenica LPS 
preparations to confirm that P. melaninogenica LPS is signaling through a TLR4 
independent pathway.  TLR2 signaling was seen previously in experiments testing 
formalin fixed P. melaninogenica on 293/hTLR-2 and 293/hTLR-4/CD14/MD2 cell lines 
(72).  Formalin fixed bacteria is a complex mixture of membrane components and does 
not represent an exclusive LPS dependent response but does show the ability for P. 
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melaninogenica signaling through TLR2 pathways.  Additionally, further experimentation 
will be needed in understanding the role of bacterial environmental growth conditions as 
it affects P. melaninogenica lipid A structure in light of heme dependent variation of lipid 
A structure leading to changes in TLR activation as seen in P. gingivalis (5, 52).  
In future studies, concurrent studies with P. melaninogenica and P. aeruginosa 
should be investigated because P. melaninogenica is more often associated within a 
group of organisms such as its presence in the oral biofilm (34) than as a single species 
infection. In experiments mimicking the environment of COPD, P. melaninogenica 
lysates inhibited the ability of Haemophilus influenzae lysates to stimulate TLR4 
signaling in dendritic cells, resulting in reduced IL-12 production (51).  Similarly, LPS 
from the closely related oral bacterium, P. gingivalis can act as a TLR4 antagonist and 
dampen or eliminate the effect of E. coli LPS on activating CHO cells expressing human 
TLR4, human THP-1 monocytes or murine macrophages (53, 71).  Because of the 
presence of P. melaninogenica in polymicrobial environments such as CF, the 
dampening effect of P. melaninogenica lysate and P. gingivalis LPS dependent 
inhibiting properties, P. melaninogenica LPS may actually provide protection to other 
organisms such as P. aeruginosa by preventing or dampening the pro-inflammatory 






































Figure 3.1. Structure of P. melaninogenica endotoxin A) Negative ion MALDI TOF mass 
spectrum of lipid A from Pm. Inset structure is proposed structure for ion at m/z 1754 
corresponding to a diphosphoryl penta-acylated lipid A structure.  B) Negative ion 
MALDI FTMS MS2 mass spectrum of precursor ion at m/z 1674. Inset structure is 
proposed structure for ion at m/z 1674 corresponding to a monophosphoryl penta-
acylated lipid A structure. Acyl chain configuration for the mono- and diphosphorylated 
lipid species were identical. Diagnostic cross-ring product ions (0,2A2 and 
0,4A2) are 
























Figure 3.2. P. melaninogenica LPS stimulates THP1 cells significantly less than P. 
aeruginosa LPS. A) IL-8 production from THP1 cells stimulated for 24 hours with P. 
melaninogenica LPS or P. aeruginosa LPS. B) IL-1β response of THP1. IL-8 and IL-1β 
measured by ELISA. Graph displays mean and standard deviation of three independent 
experiments in triplicate P<0.05. ND= not detectible.  
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Figure 3.3. P. melaninogenica stimulates NFĸB and IL8 production in a TLR4 
independent mechanism. A) NFĸB activation and B) IL-8 production by THP1 cells with 
TLR4 neutralizing antibody.   NFĸB measured by Quanti-Blue. IL-8 measured by ELISA. 
Anti-TLR4- 5µg/ml, mAb IgG- 5µg/ml, Purified E. coli LPS- 50ng/ml, P. melaninogenica 
10µg/ml. Results are means and standard deviations of triplicate wells and are 









Figure 3.4. P. melaninogenica LPS NFĸB and IL-8 production response with TLR 2 
antibodies. A) NFĸB activation and B) IL-8 production by THP1 cells with TLR 2 
neutralizing antibody.  NFĸB measured by Quanti-Blue. IL-8 measured by ELISA. P. 
melaninogenica 10µg/ml. Anti-TLR2- 5µg/ml, mAb IgG- 5µg/ml,Pam3CSK3-10ng/ml, P. 
melaninogenica 10µg/ml. Results are means and standard deviations of triplicate wells 
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 Chapter 4. 




Prevotella melaninogenica, an anaerobic Gram-negative bacterium, has been 
cultured from polymicrobial disease sites including the lungs of patients suffering with 
the genetic disease cystic fibrosis (CF). In the CF lung, like other disease sites, bacteria 
must acquire essential nutrients such as iron. To better understand how P. 
melaninogenica survives in the CF lung, we characterized the ability of the bacterium to 
utilize relevant host sources of iron. In vitro growth experiments showed that P. 
melaninogenica growth depends on the presence of heme or hemoglobin and that other 
host iron containing proteins such as lactoferrin and transferrin or various inorganic iron 
molecules cannot serve as a sole iron source. To identify potential hemoglobin 
acquisition systems of P. melaninogenica, we sequenced the genome of the typed 
reference strain 25845 and searched for homologues of known hemoglobin receptors. 
We found several putative hemoglobin receptors through amino acid homology and 
predicted membrane topology.  We also used hemoglobin agarose beads to identify 
outer membrane proteins that bind hemoglobin and searched for surface proteins that 
were heme-iron regulated. Using a combination of approaches, we have identified a 
comprehensive list of putative P. melaninogenica hemoglobin receptors.  Future 
studies, with the aid of a P. melaninogenica genetic system, will further the 
characterization of heme acquisition in P. melaninogenica.   
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Introduction:  
P. melaninogenica, formerly Bacteroides melaninogenicus, is a black pigmented 
anaerobic, Gram-negative bacterium with several potential virulence characteristics 
including fimbrial hemagglutination and the production of hemolysin, β-lactamases, 
fibrinolysin and a variety of proteases (193-196).  P. melaninogenica was historically 
considered an oral commensal; however, it has recently been described as a potential 
pathogen and is closely related to other species considered highly pathogenic (197-
199).  P. melaninogenica has been cultured as the sole infectious agent from abscesses 
associated with vertebral osteomyelitis, pyomyositis and vaginal mesh infections (200-
202).  In addition, P. melaninogenica has been documented in polymicrobial diseases 
including brain abscesses, pleuropulmonary infections, endocarditis, intra-abdominal 
infections, wound infections, necrotizing fasciitis, decubitus and diabetic ulcers (194, 
203-205).  
P. melaninogenica was the most common anaerobe reported in sputa from adult 
cystic fibrosis (CF) patients (197, 206).  Both culture based methods and molecular 
techniques show P. melaninogenica in the CF lung (197, 207-214).   CF is the most 
common lethal genetic disorder affecting Caucasians. In the lungs of CF patients, 
dehydrated mucus forms hypoxic and/or anaerobic plaques that are suitable 
environments for anaerobic bacterial colonization (215, 216).  In CF, cycles of infection, 
followed by chronic airway colonization cause excessive and unproductive pulmonary 
inflammation eventually leads to lung dysfunction, respiratory failure and death. The 
ability of P. melaninogenica to survive in this CF airway environment and colonize 
mucus plaques is dependent on its capacity to acquire essential nutrients, such as iron. 
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Iron is a nutritional requirement of extreme importance. For aerobic bacteria, iron 
is a required cofactor for metabolism including the electron transport chain cytochromes 
(217). For anaerobic bacteria, fumarase, iron-sulfur compounds and other iron 
containing molecules protect against superoxide and are involved in ATP production 
through pyruvate aided fermentation (218).  Within the human body, free iron is scarce 
due to the presence of iron ‘withholding’ proteins, such as hemoglobin, lactoferrin and 
transferrin, which protect from the host from hydroxyl radical production (219). These 
iron withholding proteins also deny colonizing bacteria access to iron as an essential 
growth factor (nutritional immunity) and thus represent an important host defense 
strategy against infection (218-220). The lung environment in chronically infected CF 
patients has more available iron than that of healthy individuals (217, 219, 221, 222).  
Significant amounts of iron is found in sputum and bronchoalveolar lavage (BALF) 
samples from CF patients in the form of lactoferrin, transferrin, heme and hemoglobin 
(217, 219, 222), suggesting that this environment would be prone to bacterial 
colonization.  
Because hemoglobin stores more than two-thirds of the body’s iron, bacteria 
have developed a highly complex mechanism to acquire iron from hemoglobin. (223). 
Iron is stored in the heme component of hemoglobin. Heme consists of iron complexed 
inside a protoporphyrin IX (PPIX) ring, which aids in oxygen transportation.  The 
process of heme iron acquisition begins when hemoglobin is bound to a beta barrel 
transmembrane surface receptor; it is believe that hemoglobin is then degraded to 
release heme molecules, although the specific mechanism is unknown (224-227).  
Heme is then transported across the outer membrane via a TonB dependent 
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mechanism (228) that derives energy from the inner membrane proton motive force 
(42). Specialized heme binding motifs such as FRAP and NPNL domains aid in receptor 
binding and heme transport (226).   Hemoglobin receptor expression is typically 
regulated by iron availability via the iron-regulated transcription factor Fur (229, 230).  
When iron is replete, Fur complexes with iron and binds to fur box promoter sequences 
and inhibits transcription (231, 232), Under iron depleted conditions, apo-Fur cannot 
bind to target promoters, thus allowing transcription of iron regulated genes, such as 
those encoding a bacterial hemoglobin receptor.  Once in the periplasm, heme is 
transported to an ATP-binding cassette (ABC) transporter by a heme permease into the 
cytoplasm, where heme can be used as a bacterial iron source (broken down into PPIX, 
iron biliverdin and CO2) or can be complexed with other molecules and used for oxygen 
resistance (catalase) and electron transport (cytochromes) among many other functions 
(233, 234).  
In addition to iron, Bacteroides species like, P. melaninogenica, Prevotella 
intermedia and P. gingivalis require heme itself for growth. Numerous bacterial species, 
including P. gingivalis and P. intermedia must rely on exogenous heme for growth 
because they lack the full complement of genes encoding the enzymes necessary for 
de novo heme biosynthesis (235, 236). Outer surface black pigmentation, characteristic 
of Prevotella and Porphyromonas genera, is formed from a derivative of heme and can 
to be used for oxygen protection and nutrient storage (237, 238). The ability of P. 
melaninogenica to acquire heme iron from host proteins is not known. Defining the 
mechanism of heme iron acquisition through hemoglobin in P. melaninogenica would 
provide a greater understanding into how P. melaninogenica grows in the CF lung.  
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Because of the high occurrence of P. melaninogenica in CF patients and its 
pathogenic potential, this study aims to further understand P. melaninogenica 
colonization of the CF lung by elucidating essential host iron sources and the 
mechanism of heme acquisition. We found that P. melaninogenica is able to utilize CF-
relevant iron sources such as hemoglobin and heme when grown in vitro but no other 
host iron carrying proteins such as transferrin or lactoferrin or inorganic sources of iron. 
We also demonstrated that P. melaninogenica can use heme as a sole iron source in 
vitro.  To facilitate the investigation of iron procurement, specifically the mechanism of 
hemoglobin acquisition, we sequenced the complete genome of 25845 and identified 
candidate genes involved in hemoglobin (heme) binding and transport.  We used an E. 
coli system, E. coli K12 hemA that lacks an endogenous hemoglobin receptor to test 
candidate receptor function. Finally, we investigated outer membrane hemoglobin 
binding and heme iron regulated proteins by hemoglobin affinity pull down experiments 
and outer membrane protein expression in heme deplete and replete conditions.  
Materials and Methods: 
Bacterial Strains: P. melaninogenica ATCC 25845 was obtained from ATCC and 
maintained on Columbian Blood Agar (Thermo Scientific). EB53 (K12::hemAaroB) and 
IR754 (K12::hemAaroBtonB) strains were maintained on Luria-Bertani media (LB) 
plates with carbenicillin 30 µg/ml with 300µM 5- aminolevulinic acid (ALA; Sigma)(239). 
All strains, plasmids and primers are listed in Table 1.  
Bacterial Growth Conditions: P. melaninogenica ATCC 25845 was cultured from frozen 
glycerol stock anaerobically on Columbian Blood agar plates for two to four days until 
colonies displayed a characteristic red/brown phenotype. Colonies were then inoculated 
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into prereduced Tryptic Soy Broth (Becton Dickinson) supplemented with 5 µg/ml 
menadione (Sigma) and 150 µM of 2 2'-bipyridyl (BPD, Sigma). (240).  All anaerobic 
Tryptic Soy Broth (ATSB) has menadione supplementation (241). All anaerobic growth 
was done in a Coy Anaerobic chamber at 37°C. Once growth had reached an optical 
density (OD) at 600nm OD 1.0, approximately 1x103 CFU/ml was inoculated into ATSB 
with various iron and heme conditions and in some cases 100 µM BPD. Iron sources 
were normalized to 7.6 µM iron and bacteria were grown shaking anaerobically for the 
time stated. Aliquots of media were used to measure OD600 at various time points.  
Heme stock was dissolved in 1 M NaOH. Hemoglobin stock was dissolved in water. 
Lactoferrin, transferrin, ferric citrate, ferric chloride and ferrous chloride tetrahydrate 
stocks were dissolved in DMSO.      
Genome Sequencing: Genomic DNA from P. melaninogenica ATCC 25845 was 
harvested from a one liter flask grown in Anaerobic Broth (BD Difco) and prepared using 
Fast DNA Spin Kit (MP Biomedicals). The gDNA was sequenced and assembled using 
454 and Ilumina Solexa sequencing systems similar to (242).  
Amino acid homology and topology mapping for hemoglobin receptors: To search for 
homologous proteins, P. melaninogenica sequences were investigated via BLAST-p 
and were compared using ClustaW (243, 244). Protein sequences were then imported 
into PREZ-TMD for topology mapping (245).  
E. coli hemA system: The K12 ∆hemAaroB strain (EB53) is dependent on exogenous 
heme due to the inactivation of heme biosynthesis (hemA) and iron siderophore (aroB) 
pathways (239).  The K12 ∆hemAaroBtonB strain has an additional mutation 
inactivating the TonB protein which restricts the ability to actively transport molecules to 
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the periplasm. K12 ∆hemA strains can be chemically complemented with 300 µM 5- 
aminolevulinic acid (ALA, Sigma) to restore a functional heme biosynthesis pathway 
and growth.  P. melaninogenica candidate outer membrane receptors were expressed 
by an isopropyl b-D-thiogalactopyranoside (IPTG, Sigma) inducible promoter from 
plasmid pMMB which was adapted for Gateway cloning (Life Technologies) (246). P. 
melaninogenica TonB complex (tonB, exbD (1), exbD (2), exbB), was expressed by 
tetracycline cassette promoter on pACYC184. Strains were maintained on 300 µM ALA 
(Table 1). For hemoglobin candidate evaluation, strains were plated on 100 µM IPTG 
and 10 µM hemoglobin or 100 µM IPTG and 10 µM heme plates. 
Hemoglobin agarose: Zwittergent solubilized bacteria grown under heme depleted 
conditions (no heme) were incubated with Affi-Gel 10 beads covalently attached to 
solubilized human hemoglobin. Hemoglobin bound proteins were eluted with elution 
buffer (1% octylglucoside/1.5% glycine pH 2.3)  then run on 7.5% gradient SDS page 
gel as described (247). Putative P. melaninogenica hemoglobin binding proteins were 
viewed by Sypro Ruby staining (Bio-Rad). Proteins were excised and digested in gel 
with trypsin and the resulting peptides were analyzed by ABI 4800 MALDI TOF/TOF MS 
by the UNC Proteomics Core. 
Outer membrane preparation (OMP): Bacteria were grown in one liter of ATSB under 
either heme deplete (0 µM heme) or heme replete (7.6 µM heme) conditions as 
described in (248, 249) until stationary phase. Bacteria were harvested by centrifugation 
at 10,000 x g for 25 minutes at 4°C. Supernatant were removed and the pellets were 
suspended in lysis buffer (50 mM NaH2PO4, pH 7, 300 mM NaCl) with 1 mg/ml 
lysozyme and incubated on ice for 30 minutes. The material was lysed by two passages 
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through a French pressure cell.  Intact cells and cell debris were removed by 
centrifugation at 10,000 x g for 20 minutes at 4°C. Supernatant were centrifuged at 
100,000 x g for 1 hour at 4°C. The pellet were solubilized in 1% Sarkosyl and 
resuspended with a syringe 27G (Becton Dickinson) 4 times and incubated for 30 
minutes at room temperature with gentle shaking.  The Sarkosyl soluble faction was 
subjected to centrifugation at 100,000 x g for 1 hour at 4°C. The supernatant fraction 
was removed and the pellet was resuspended in 100 µl PBS to yield the outer 
membrane preparation.  4 µgs of OMPs were suspended in SDS-PAGE sample buffer 
and heated to 100°C for 5 minutes. Samples were run on a 7.5% Mini-protean TGX 
(Bio-Rad) gel and were stained with GelCode Blue Stain Reagent (Thermo Scientific).   
iTRAQ analysis: 70 µgs of OMPs from either heme depleted or heme replete P. 
melaninogenica were collected and stored in 8 M urea. iTRAQ analysis was done by 
UNC Proteomics core.  
Results:  
Characterization of P. melaninogenica iron requirements.  
Fastidious black pigmented Bacteroides species, including P. melaninogenica, 
are routinely grown in complex blood media and have a characteristic black heme 
derivative stored on the outer surface of the bacterium.  In order to deplete heme iron 
stores Bacteroides species must be grown in serial passages on media lacking a heme 
source. To establish the iron growth requirements of P. melaninogenica, we first 
determined the effect of iron containing sources on the growth of P. melaninogenica 
after passages in heme depleted ATSB. In the absence of supplementation, P. 
melaninogenica is unable to grow in ATSB (Figure 1A). Supplementation of ATSB with 
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heme or human hemoglobin is sufficient to restore growth (Figure 1A and 1B). In 
contrast, other human iron containing proteins, readily available in infected airways 
(lactoferrin and transferrin) were not sufficient to support growth (Figure 1A).  Inorganic 
forms of iron such as ferric citrate (Fe 3+) ferric chloride (Fe 3+) ferrous chloride 
tetrahydrate (Fe 2+) did not support P. melaninogenica growth in ATSB (Figure 1B). 
These inorganic forms were used to test if the oxygen state of the iron molecule and the 
iron solubility at physiological pH would promote growth in an anaerobic atmosphere 
(250). We also demonstrated that P. melaninogenica can use heme as a sole iron 
source in iron restricted chelated ATSB media (Figure 1C). However, growth in chelated 
conditions was not as robust on heme alone; suggesting that trace inorganic iron 
present in ATSB can be utilized.  Additionally in the presence of inorganic iron, PPIX, a 
protoporphorin lacking iron, can be used to restore growth to similar rates as heme in 
ATSB (Supplementary Figure 1).   
 
The P. melaninogenica genome sequence reveals iron acquisition system 
candidates.   
To investigate the mechanism of iron/heme acquisition, we sequenced the P. 
melaninogenica genome to facilitate the identification of genes involved in hemoglobin 
(heme) binding and transport.  In collaboration with Dr. Corbin Jones (UNC-CH 
Department of Biology) and Dr. Anthony Fodor (UNC-C Department of Bioinformatics 
and Genomics) we used 454 pyrosequencing in combination with the Ilumina-Solexa 
platform, to sequence the complete genome of P. melaninogenica ATCC 25845.  The 
sequence is currently partially assembled. The genome is approximately 3.2 million 
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base pairs, contains over 2700 putative open reading frames (ORFs) and is predicted to 
be organized into two chromosomes.  The combination of both platforms enabled 
confident structuring and assembly (242). However, prior to the completion of our 
genome sequencing efforts, the genome sequence for P. melaninogenica ATCC 25845 
was submitted to NCBI by the J. Craig Venter Institute, as a part of the Human 
Microbiome Project (HMP) Reference Genomes (251).   
The submitted P. melaninogenica genome sequence (ACSI00000000) was used 
to identify candidate genes involved in iron acquisition (Figure 2A and 2B).  Using 
BLASTn, we found genes encoding secreted proteins such as hemagglutinin and 
hemolysin (196) , which are proposed to aggregate and lyse red blood cells.  In terms of 
candidate heme and/or hemoglobin receptors, we identified 19 putative TonB 
dependent outer membrane proteins in addition to many TonB dependent plug domains 
(not shown).  Even though there are no siderophore like proteins encoded by P. 
melaninogenica there is a TonB-dependent siderophore receptor that could be used to 
scavenge siderophores in multispecies environments.  
 The energy required for heme-iron transport across the outer membrane is likely 
supplied by a unique P. melaninogenica TonB complex.  Four genes, encoding TonB, 
ExbB, ExbD1and ExbD2 proteins were found. Many bacteria have a single exbD; we 
hypothesized the additional gene could play an auxiliary role in iron acquisition.  Once 
heme is transported to the periplasmic space, a putative heme permease transports 
heme to an inner membrane bound ABC transporter. P. melaninogenica also encodes 
feoB for inorganic iron transportation into the cytoplasm revealing the importance of 
inorganic iron to P. melaninogenica growth (Figure 1C). Further, P. melaninogenica 
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encoded several cytoplasmic proteins related to iron metabolism including two fur genes 
homologs, ferritin and bacterioferritin, but was missing key heme biosynthesis pathway 
genes such as ferrochelatase.  RT-PCR studies with the two fur homologs show a 
different regulation pattern from each other suggesting different roles for each protein 
(Supplementary Figure 2). Additionally the lack of an encoded ferrochelatase, an 
enzyme that inserts iron into the PPIX ring, in the P. melaninogenica genome does not 
explain the apparent usage of PPIX in place of heme (Supplementary Figure 1).   
 
Identification of P. melaninogenica candidate hemoglobin receptors through 
amino acid homology searches.   
More extensive searches incorporating characteristic hemoglobin receptor motifs 
and membrane topology predictions revealed a small group of proteins resembling the 
well characterized hemoglobin receptor ShuA from S. dysenteriae (226) and HmuR P. 
gingivalis (230, 236) (Figure 3). Specifically, amino acid homology using conserved 
residues from other characterized hemoglobin receptors such as the FRAP and NPNL 
domains, TonB box (TVTATG) and outer membrane transmembrane beta barrel 
structure was used (226, 252). Two proteins, HMPREF0659_A5369 (designated HmuR) 
and HMPREF0659_A6271 (designated TonBr) showed similarity to both ShuA from S. 
dysenteriae and HmuR of P. gingivalis using these methods.  
Characterization of candidate P. melaninogenica hemoglobin receptors using E. 
coli hemA.  
 To functionally characterize the genes identified in our analysis of the 
sequenced genome, we utilized an E .coli K12 based screening strain (239). E. coli K12 
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strains naturally lack an endogenous hemoglobin receptor but are capable of de novo 
synthesis of heme. To eliminate heme biosynthesis the screening strain carries a 
mutation in hemA (encoding glutamyl-tRNA reductase). The HemA gene product is 
required for the production of 5-aminolevulinic acid (ALA), a precursor in the heme 
biosynthesis pathway (253). To reduce growth under iron limiting conditions, the 
screening strain also carries a mutation in aroB, which is required for siderophore 
production. For growth under iron limiting conditions, the E. coli K12 hemA, aroB double 
mutant (K12 hemAaroB) can be chemically complemented with ALA or genetically 
complemented by expression of a functional heme/hemoglobin receptor (Figure 4A). 
We chose the following hemoglobin receptor candidates based on homology scores. 1) 
P. melaninogenica A5369 ‘HmuR’, a TonB-dependent receptor, sharing 29% amino acid 
sequence similarity with the heme utilization receptor (HmuR) of P. gingivalis, 2) P. 
melaninogenica A7242 ‘OmpHb’, a putative TonB-dependent receptor plug domain 
protein (44% similarity to PhuR of Flavobacterium psychrophilum) and 3) P. 
melaninogenica A6271 ‘TonBr’, a putative TonB-dependent domain protein (45% 
similarity to an outer membrane heme/hemoglobin receptor of S. dysenteriae). The 
K12hemAaroB strain was used to test the candidate P. melaninogenica genes and 
known hemoglobin receptors from other species for their ability to restore growth in the 
absence of ALA. The panel of P. melaninogenica receptors showed no function in the 
heterologous E. coli background when grown on hemoglobin or heme, in contrast to a 
putative E. coli hemoglobin receptor (C1129, Figure 4B).  To rule out the possibility that 
the candidate heme/hemoglobin receptors are incompatible with E. coli TonB, as has 
been reported in other systems (239), we cloned the putative P. melaninogenica TonB 
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complex (tonB-exbD-exbD-exbB) and expressed the candidate P. melaninogenica 
receptors and TonB complex genes in K12hemAaroBtonB an isogenic mutant of 
K12hemAaroB (Figure 4B). However, the P. melaninogenica TonB complex did not 
restore growth to K12hemAaroBtonB whereas expression of E. coli TonB protein 
restored function of the E. coli hemoglobin receptor (data not shown).  
Our results suggest that the P. melaninogenica candidate hemoglobin receptors 
do not have the proposed function and/or the P. melaninogenica TonB complex and 
hemoglobin receptor systems are not functional in E. coli K12. Because we were unable 
to distinguish these possibilities, we chose several alternative methods to further pursue 
the identification of P. melaninogenica hemoglobin receptors.  
 
Identification of P. melaninogenica hemoglobin receptors by hemoglobin affinity 
purification. 
 To purify P. melaninogenica hemoglobin binding proteins, we mixed heme 
starved P. melaninogenica lysate with Affi-gel 10 beads covalently attached to human 
hemoglobin (254). In parallel experiments hemoglobin agarose was used to isolate 
HgbA from heme starved H. ducreyi (239, 254). Using the hemoglobin pull down 
technique, several putative P. melaninogenica hemoglobin binding proteins were 
identified by MALDI TOF/TOF MS (Figure 5). The top candidates were 
HMPREF0659_A5491 putative outer membrane protein involved in nutrient binding, 
HMPREF0659_A7287 TonB-dependent receptor plug, HMPREF0659_A5179 putative 
RagA protein, HMPREF0659_A6276 TonB-dependent receptor and 
HMPREF0659_A6366 putative outer membrane protein. Despite the clear enrichment 
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of these proteins by hemoglobin affinity-based purification, none possessed all the 
predicted sequencing characteristics of known heme/hemoglobin receptors as 
described above.  
 
Identification of P. melaninogenica hemoglobin receptors by enrichment under 
heme starved conditions.  
Because iron acquisition is such an important growth requirement, bacteria 
regulate iron acquisition by controlling the amount of surface expressed iron receptor.  
Based on this widespread regulatory feedback mechanism, we hypothesized that P. 
melaninogenica hemoglobin receptors may be enriched under heme starved conditions. 
To enrich for iron regulated proteins, an outer membrane preparation was made under 
heme and iron limiting conditions sited in previous papers for other closely related 
bacteria (235, 238, 240, 248, 249). In addition, specific P. melaninogenica growth 
conditions were tested using in vitro growth curves that showed slow stunted growth 
characteristic of limited nutrient availability.  
The P. melaninogenica proteins from heme replete and deplete conditions were 
analyzed by SDS-PAGE and isobaric tags for relative and absolute quantitation 
(iTRAQ), a quantitative method to identify peptides in a complex mixture (255). Both of 
the heme regulation experiment used (SDS-PAGE and iTRAQ) used the identical OMP 
preparation.  SDS-PAGE analysis of the outer membrane preparations revealed 
multiple potential heme regulated proteins (Figure 6A and Figure 6B). The iTRAQ 
method showed four proteins that were regulated by heme, one of which fit the outer 
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membrane location and heme binding motif criteria characteristic of hemoglobin 
receptors (Figure 6C).  
Using the collective information from the various analyses described above, we 
identified a total of 24 putative hemoglobin receptors. Of these, seven candidates 
possess known hemoglobin receptors predicted topology, heme binding motif 
signatures, hemoglobin binding and heme regulation.  
Discussion 
In order to colonize a host, bacteria must have the ability to acquire limited but 
essential nutrients. In the human host, iron, an essential nutrient, is sequestered by 
carrier molecules and proteins such as heme, hemoglobin, lactoferrin and transferrin. 
These high affinity iron binding molecules control iron toxicity and facilitate important 
metabolic processes (217-220). In CF chronic lung disease, a considerable quantity of 
free heme and hemoglobin is available inside the lumen of the airways (217, 219, 221) 
making a suitable niche for bacterial colonization.   
Our results using in vitro growth conditions show that P. melaninogenica can use 
both heme and hemoglobin to support grow. Earlier studies, using a clinical isolate, 
established that P. melaninogenica can secrete a hemolysis capable of degrading 
hemoglobin (196).  In addition, we demonstrated that P. melaninogenica can use heme 
as an iron source by growing P. melaninogenica in iron restricted media. With 
hemoglobin and heme as known growth sources, further experiments elucidated the 
mechanism for heme acquisition through hemoglobin receptors. Moreover, the P. 
melaninogenica genome does not encode for a typical ferrochelatase or ferrochelatase 
enzyme homolog that inserts or removes iron from the PPIX ring, but P. melaninogenica 
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can use heme as an iron source (Figure 1C) and can grow on PPIX in an iron rich 
environment (Supplementary Figure 1).  Future studies are needed to identify the 
enzyme used for removal and insertion of iron into the heme molecule.  
The P. melaninogenica genome provides clues to the mechanism(s) of heme 
acquisition.  Based on the genome sequence, we identified nineteen putative TonB 
dependent outer membrane receptor/transporters and a complete ABC transport 
system and permease with homology to known periplasmic and inner membrane iron 
transport systems (Figure 2B). The TonB system of P. melaninogenica, encodes for two 
exbD genes like Flavobacterium psychrophilum (256) and Xanthomonas campestris 
(257).  In X. campestris, a Gram-negative plant pathogen, only one of the exbD genes is 
involved in iron uptake. The function of exbD1 and exbD2 for P. melaninogenica are 
unknown. In addition, P. melaninogenica encodes two Fur proteins proposed to regulate 
fur dependent genes. Other bacteria like Campylobacter jejuni (258) and Bacillus 
subtilis (259) contain multiple fur homologues. In preliminary testing, only one candidate 
fur gene showed differential regulation in response to iron availability (Supplemental 
Figure 2).  Interestingly, P. melaninogenica does not encode identifiable iron 
scavenging proteins like siderophores or gingipains, suggesting that the CF lung 
environment provides an ample supply of usable iron.  
The P. melaninogenica genome search for hemoglobin receptors revealed 
multiple proteins that had hemoglobin receptor characteristics. One interpretation of 
these results is that P. melaninogenica does not just rely on one but several receptor 
proteins, as seen in P. gingivalis (260).  P. melaninogenica, a black pigmented 
anaerobe like P. gingivalis, is covered in black heme-derived pigment that could be 
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attached by surface receptors that do have the ability to transport but when heme is not 
needed, hold the heme on the surface for storage and oxygen protection purposes 
(238).  Theoretically there could be several hemoglobin receptors that each transport 
heme (or different heme forms) when needed.    
Because P. melaninogenica, like other a black pigmented Bacteroides species, 
can store a heme iron derivative on its surface, heme starvation conditions are difficult 
to achieve without serial passage in iron depleted conditions. Optimal starvation 
conditions were needed to detect altered expression of iron regulated proteins in lysate 
preparations for hemoglobin agarose pull-downs and outer membrane preparations by 
gel electrophoresis and iTRAQ.  The difficulty in achieving consistent depletion 
conditions may account for the variation in the results of each of these experiments.  
Additionally, because of the inability to genetically manipulate P. melaninogenica, an E. 
coli system was used as a method of localizing one protein and testing function instead 
of doing function assays with a P. melaninogenica mutant. The E. coli hemA system 
had been used in the past to demonstrate hemoglobin receptor function (253, 261).   
However, top candidates for P. melaninogenica hemoglobin receptor did not restore the 
E. coli hemA system. This led us to rethink the candidates for selection and the 
compatibility of P. melaninogenica proteins with E. coli protein machinery.  
Taken together our data suggests that P. melaninogenica hemoglobin receptors 
are expressed and function to acquire hemoglobin as demonstrated in in vitro growth 
assays. Further studies in hemoglobin receptor identification will be greatly aided by the 
development of genetic systems in P. melaninogenica. Work done to further 
characterize hemoglobin receptors, to understand the mechanism of cytoplasmic heme-
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iron removal, to characterize two putative Fur proteins and to investigate fur-dependent 























































ATSB + Human Hemoglobin
ATSB + Apo Lactoferrin
ATSB + Holo Lactoferrin

















ATSB + Ferric citrate
ATSB + Ferric chloride














C.   

















Figure 4.1  P. melaninogenica requires heme or hemoglobin to grow in ATSB. A) 
Growth of P. melaninogenica in ATSB with host iron sources normalized to 7.6 µM iron. 
Molar equivalences as follows: One mole hemoglobin contains four moles of heme. One 
molar heme molecule contains one molar iron. One mole lactoferrin/transferrin contains 
two mole of iron. B) Growth of P. melaninogenica in ATSB with inorganic sources of iron 
such as ferric citrate, ferric chloride and ferrous chloride tetrahydrate normalized to 7.6 
µM iron. The average of three experiments was plotted and standard deviation of each 
point is depicted. C) Growth of P. melaninogenica in 100 µM BPD chelated ATSB. The 







































   
    
    
Figure 4.2 P. melaninogenica iron and heme-iron acquisition system. A) Pictorial representation of putative P. 
melaninogenica heme/hemoglobin acquisition machinery.  Light pink boxes are genes encoding for putative hemoglobin 
receptors. The dark green oval represents heme permease and white boxes represent the P. melaninogenica TonB 
system. Purple boxes are representing ABC transporter. All locations were determined by author’s discretion. B) P. 
melaninogenica genes homologous to characterized heme iron acquisition systems. ** All Amino Acid Identity 
comparisons are homologous to proteins in Porphyromonas gingivalis ATCC 33277 except for those noted with $. $ 











Figure 4.3 P. melaninogenica proteins homologous to characterized hemoglobin 
receptors. A) ClustalW map of BLAST-p search of P. melaninogenica proteins. ShuA 
Shigella. P. gingivalis W83 HmuR. P. melaninogenica TonBr and P. melaninogenica 
HmuR. Colors are dependent on amino acid residue algorithms. B) PREZ-TMD 
depiction of ShuA and candidate P. melaninogenica hemoglobin receptors. Red 








Figure 4.4: Outline of experiments with E. coli K12 hemA system. A) Schematic 
representation of the properties of the E. coli hemA system. B) Growth of E. coli 
hemoglobin receptor cloned into hemA system on hemoglobin and heme plates. 
Lack of growth of candidate P. melaninogenica hemoglobin receptors cloned in E. 
coli K12 hemA system on hemoglobin and heme plates with and without the P. 
melaninogenica TonB system shown. P. melaninogenica A7242 ‘OmpHHb’. P. 
melaninogenica A5369 ‘HmuR’. P. melaninogenica ‘A6271 TonBr’.  
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Figure 4.5: Functional assessment of P. melaninogenica proteins using hemoglobin 
agarose. A) Hemoglobin agarose pull down of P. melaninogenica proteins stained 
with Sypro ruby on gradient gel. Red arrows indicate gel excised proteins B) Mass-




























Figure 4.6 Characterization of heme regulated P. melaninogenica OMPs. A) 
Gradient gel electrophoresis of P. melaninogenica grown in heme depleted and 
heme repeat conditions. B) Results from excised gel bands noted with red arrow.  C) 






Table 4. 2 Summary of P. melaninogenica candidate hemoglobin receptors. Four 
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Supplementary Figure 4.1S: P. melaninogenica can use heme and PPIX for growth 




Copies of putative P. melaninogenica fur genes in



















































Supplementary Figure 4.2S: Two fur genes differentially regulated by iron. A) RNA 
was collected from four P. melaninogenica growth conditions and RTPCR was done 
showing that Fur5773 is regulated by iron availability. Experiment done once with 
three replicates. Standard deviation graphed.  
 
 
During the mining of P. melaninogenica for heme/hemoglobin acquisition proteins, 
two putative fur proteins were found. HMPREF0659_A6606 is a transcriptional 
regulator in the Fur family located on chromosome 2, with 27% homology with P. 
gingivalis W83 Fur protein and 22% homology to E. coli O157:H7 strain. 
HMPREF0659_A5773, a transcriptional regulator in the Fur family, is on 
chromosome 1, with 28% P. gingivalis W83 Fur protein and 29% homology to E. coli 
O157:H7 strain. Comparing the two proteins Identities = 38/130 (29%), 8e-12.  RT 
primers were then made and tested with various heme and chelated conditions. 
Growth conditions were done in a similar manor as growth curves with the exception 
of the addition of BPD. The heme condition (7.6µM) represents a standard baseline 
condition for optimal growth of P. melaninogenica. Noheme+10BPD is represented 
as a low level stress (50BPD=high). Only A5773 showed regulation by heme 
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 Chapter 5 
Conclusion 
 
Cystic fibrosis lung disease 
Cystic fibrosis (CF) is the most common fatal genetic disease affecting the 
Caucasian population, with more than 30,000 individuals with CF in the United 
States (1). The prevailing phenotype in CF is a defect in mucociliary clearance of the 
airways and the accumulation of dehydrated viscous mucus, which creates an 
optimal niche for bacterial colonization.  In CF, chronic bacterial pulmonary infection 
and recurring episodes of acute pulmonary exacerbation produce an irreversible 
decline in lung function that ultimately leads to respiratory failure and death. While 
life expectancy has improved, it is still only 37 years (2). Recently, our understanding 
of the microbial landscape of the CF airway has expanded to include a more diverse 
polymicrobial community of species.  The contribution of these non-traditional 
pathogens to CF airway infection and disease progression is unknown.  
 
CF Microbiome Studies 
In the past 5 years, our understanding of CF pathogenesis has dramatically 
expanded with the application of high throughput sequencing, which has redefined 
CF airway microbiology. Historically, clinical bacterial culture in CF has focused on 
the frequency, abundance and antimicrobial susceptibility of aerobic pathogens such 
as Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa.  
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During childhood, S. aureus and H. influenzae are isolated in high abundance and 
these are gradually replaced by P. aeruginosa and Burkholderia cepacia during 
adolescence and adulthood (3, 4). While these observations still hold true, more 
recent metagenomic studies estimate the presence of more than 60 different 
bacterial genera by deep sequencing and over 43 different phyla by 16S ribosomal 
RNA (rRNA) gene-based phylogenetic microarrays (5). The most abundant genera 
commonly sampled are Pseudomonas, Streptococcus, Fusobacterium, and 
Prevotella.  As technology has advanced, lesser known facultative and strict 
anaerobic organisms associated with the oral cavity have been detected; however, 
their role in CF pathogenesis is unclear.  
 
Key Questions about CF 
Despite the apparent polymicrobial nature of CF, treatment decisions are still 
largely based on the identification of traditional CF pathogens (P. aeruginosa /S. 
aureus) and antibiotics with broad spectrum activity against Gram-negative and 
Gram-positive bacteria are used. Unfortunately, chronic antibiotic treatment 
management has become the norm (1).  Chronic bacterial infection throughout life 
produces a new baseline of ‘tolerable’ and manageable colonization and forces 
clinicians into individualized management of symptoms.  Antibiotic management of 
exacerbation status, a state when there is a sudden onset of worsening lung 
function, appears to minimally impact species diversity and microbial community 
structure, yet patients respond clinically and show improved lung function (5). This 
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disconnect reveals the complexity of CF microbiology and highlights the need for a 
deeper understanding of the CF airway microbiota.  
 
Are oral anaerobes in CF samples contamination or are they colonizing 
microbes in the CF lung?  
Most respiratory specimens are collected through the oropharynx except 
retrieval of bacteria from explanted lung samples.  Recently, two studies have 
described the presence of oral anaerobes as less abundant in explanted lungs than 
others who have cultured oral anaerobes from sputum (6, 7). Both of these studies, 
though very thorough, sampled end stage and/or deceased patients when bacterial 
diversity has been shown to be significantly reduced.  However, these studies call 
into question the reliability of microbiome studies that use samples that have passed 
through the oral cavity.  Yet, aspiration into the respiratory tract from the oral cavity 
is expected and may contribute to colonization of the lower airways (5, 8).  
Furthermore, it is possible that the oral cavity could serve as a reservoir for 
pulmonary infection in CF (4, 9). 
Most studies reporting a high abundance of anaerobes in the lungs of CF 
patients have been based on analysis of spontaneous expectorated sputum (5, 8-
25). These studies represent the traditional method of evaluating microbial diversity 
in the lungs. Comparison of concomitant mouthwash samples to lung sputum 
samples show similar species but the abundance of anaerobes in lung samples 
points to colonization verses contamination (26).  Additionally, anaerobic species 
have been cultured consecutively in longitudinal studies, demonstrating a constant 
138 
presence of anaerobes in the lungs (5, 22). While contamination is unavoidable in 
expectorated sputum samples, studies have shown a similar pattern of oral bacterial 
species in bronchoalveolar lavage fluid (BALF), obtained directly from the lower 
airways (17, 27).  
With the demonstration of steep oxygen gradients in CF mucus plugs, the 
credibility of the presence of strict anaerobes has begun to increase (28).  
Anaerobes, specifically oral-related anaerobes,  have been identified in numerous 
studies (5, 8-25, 27) with the most abundant member being Prevotella 
melaninogenica (8, 11, 15, 17, 18, 22, 23, 27). In chapter 2, we demonstrate, in a 
UNC cohort, that P. melaninogenica was present in 19 of 28 adult sputum samples 
and 19 out of 33 samples from pediatric patients, representing the most abundant 
and frequent strict anaerobe.  Furthermore independent of culture results, we show 
an increase in antibody response to P. melaninogenica in CF patients, even in 
young CF children, compared to non-disease controls (Chapter 2).  In this context, 
antibody response points to an increased exposure or presence of P. 
melaninogenica that is occurring outside the oral cavity.  
 
What is the timing of microbial development in CF?  
In CF, the loss of normal clearance mechanisms results in extensive mucus 
accumulation on the apical surface of the airways providing an ideal environment for 
bacterial colonization (19, 29). The presence of bacteria in the CF lung can occur as 
early as two months of age (10). Using oropharyngeal swab samples, a time-
dependent development of CF airway microflora, beginning with Streptococcus, 
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Veillonella, and Prevotella has been reported for pediatric patients (10).  It is unclear 
whether these bacteria truly colonize the lung or are just aspirated and cleared. In 
chapter 2, we demonstrated a similar spectrum of anaerobic species from patients 
(as young as 1 year old) with P. melaninogenica being the most prevalent and 
abundant strict anaerobe.  
Early bacterial colonization is corroborated by porcine studies (CFTR−/− 
genotype) that show an impact of defective mucociliary clearance in a matter of 
hours after birth with impaired bacterial elimination occurring in pigs as young as 8 to 
10 hours postpartum (30). An influx of neutrophils and increased inflammatory 
cytokines is seen in CF pediatric patients compared to normal controls and other 
chronic respiratory disease patients (31-33), consistent with early bacterial 
exposure.   
Bacterial colonization could contribute to these already exaggerated CF 
dependent inflammatory responses.  In chapter 3, we demonstrate that P. 
aeruginosa, the classic pathogen associated with CF, can produce a robust LPS 
dependent IL-8 response corroborating previous studies (34). In contrast, we 
demonstrated that P. melaninogenica LPS produces a low IL-8 and an undetectable 
IL-1β response in the same cell line.  These results suggest that the contribution of 
P. melaninogenica to the overall inflammatory response seen in CF may be minimal.  
As the patient ages, a diverse polymicrobial infection becomes dominated by 
P. aeruginosa and lung function decreases eventually leading to respiratory failure 
(8, 35, 36). During the transition between acute and chronic infection, P. aeruginosa 
isolates acquire mutations causing them to overproduce an alginate 
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exopolysaccharide, a process referred to as mucoid conversion (37, 38). There is 
direct evidence that P. aeruginosa are enmeshed in alginate and form biofilm 
aggregates within luminal mucus plugs (39).  Inside mucus plugs, low oxygen and in 
some cases anaerobic conditions have been measured (28).  The presence of 
anaerobes has been correlated with the presence of P. aeruginosa in several 
studies suggesting a potential benefit for each bacterial species in the development 
of the microbial niche (17, 19). In chapter 2, we also demonstrate a positive 
correlation of antibody response against P. aeruginosa and P. melaninogenica in 
children and adults.  
Outside of the mucus plugs, cellular debris and neutrophils contribute to the 
nutrient rich inflammatory environment. Elevated iron in the form of ferritin, 
lactoferrin, heme and hemoglobin has been observed in the lumen of CF patients 
compared to healthy individuals and disease controls (40, 41).  Work in chapter 4 
focuses on the ability of P. melaninogenica to use available host based iron sources 
for growth, and describes potential heme acquisition systems. This combination of 
anaerobiosis and usable nutrients provides the ‘perfect storm’ for colonization by a 
large range of species including fastidious anaerobic bacteria.  
 
What is the role of anaerobes in CF pathogenesis?  
Fastidious organisms, not commonly cultivated by standard laboratory 
procedures, are now being detected in the CF lung but their role in CF airway 
disease remains unclear and controversial.    
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The Streptococcus milleri group (SMG)(composed of S. constellatus, S. 
intermedius, and S. anginosus) and oral related Streptococcus species (S. salivarius 
and S. parasanguis) have been detected in several studies using culture 
independent techniques (9, 12, 20, 42).  The original motivation for investigating 
Streptococcus species was their ability to change P. aeruginosa pathogenicity by 
modulating virulence factor expression in a polymicrobial infection model (43). These 
studies lead Sibley and colleagues to investigate the connection between CF 
exacerbation and the presence of the SMG (9). By culturing samples from a small 
cohort of patients longitudinally, they found that abundance of the SMG correlated 
with exacerbation state. Later, Filkins et al., sampled 35 patients and noted the 
abundance of the SMG and oral related Streptococcus species was not associated 
with exacerbation. In fact, they found that the presence of Streptococcus species in 
respiratory specimens correlated with stable CF disease. The authors noted that 
Streptococcus colonization was the strongest predictor of stable disease and 
concluded that it was advantageous in keeping higher diversity of the patient 
microbiota (12). Each of these groups, one while studying a single snapshot of the 
lung microbiota and the other studying longitudinal samples of a few patients, came 
to differing conclusions leading to uncertainty about the impact of Streptococcus 
species in infection.  It is important to note here that in a complex polymicrobial 
community such as in CF it is extremely difficult if not impossible to assign cause 
and effect.   Each bacteria or community of bacteria can have a clear association 
with health or disease state but that does not equate to cause (4, 44, 45).   
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The diversity of microbes present in the CF microbiome appears to be 
beneficial to lung health if total bacterial eradication is not an option (5, 12).  
Bacterial ‘space holders’ taking the place of a traditional pathogen could represent a 
more favorable environment than a chronic P. aeruginosa infection.  Even though 
there is not a correlation of P. melaninogenica with health or disease stability 
(Chapter 2), we hypothesize that community composition rather than total bacterial 
burden may impact disease state (12).  With the identification of lesser-known 
species in high abundance in CF airways, mechanistic studies are sorely needed to 
elucidating the contribution of these organisms to disease pathogenesis.  
Anaerobic species have been detected in many studies of the CF microbiome 
(5, 8-25, 27) and have the potential to effect the pathogenesis of CF.  P. 
melaninogenica, the subject of this dissertation, was the most frequently associated 
strict anaerobic species in CF in both adults and pediatric patients (Chapter 2).  Oral 
species occupying the CF niche could lead to nutrient fluctuation and depravation in 
the environment causing a regulatory change in the primary pathogen (9, 43). Duan 
et al. shows that in the presence of an oral commensal, P. aeruginosa virulence can 
be greatly enhanced or reduced depending on the commensal present. In a mouse 
model of pneumonia, the addition of a Prevotella species with Streptococcus 
constellatus caused a 6 fold increase in mortality of the mouse (46). Additionally, the 
presence of anaerobes could preserve a diverse multispecies community in order to 
delay or prevent the dominance of P. aeruginosa in the CF lung.  
It remains unclear as to whether anaerobes are detrimental or beneficial in 
the context of CF airway infection and disease progression. Investigating the role of 
143 
P. melaninogenica in the CF lung in chapter 2, we found no significant correlation 
with the presence (CFU/ml) or IgG response to P. melaninogenica with clinical 
measurements of lung function. The clinical relevance of P. melaninogenica or other 
oral anaerobic bacteria must be assessed by clinical trials that treat aerobic bacteria 
compared to treatment regimes that combine treatment towards anaerobic and 
aerobic bacteria (18). 
 
Conclusions 
We have shown that oral anaerobes are present in samples collected from 
pediatric and adult CF patients. Exposure to oral anaerobes, specifically P. 
melaninogenica, is corroborated by our studies investigating P. melaninogenica 
reactive antibody response. We show that CF patients, both pediatric and adult, 
demonstrate a higher antibody response than non-diseased and healthy control 
groups. Initial studies investigating P. melaninogenica LPS illustrate that P. 
melaninogenica could minimally contribute to the overall increased cytokine 
response seen in CF patients.  Additionally, within the CF lung, we establish that P. 
melaninogenica has the ability to survive and growth with available host iron proteins 
demonstrated to be in high abundance in the CF lung. The presence of oral 
anaerobes in our studies is undeniable but their role in CF infection remains to be 
determined.   
In summary, I believe that early aspiration of oral commensals into the lungs 
of pediatric CF patients leads to initial exposure to oral bacteria. As the anaerobic 
niche develops, transient exposure of anaerobes leads to stable colonization. These 
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anaerobic and highly nutrient rich mucus plug likely house anaerobic bacteria until 
colonization of P. aeruginosa becomes predominant. Chronic P. aeruginosa infection 
then dominates the CF landscape leading to a decrease in microbial diversity, 
overwhelming inflammation, lung dysfunction and respiratory failure.  Treatments 
that simultaneously tip the balance from an inflamed and infected to hydrated and 
healthy airway surface are desperately needed to circumvent the progression of CF 



















1. Ratjen F, Döring G. Cystic fibrosis. The Lancet. 2003 2/22;361(9358):681-9. 
2. LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol 
Rev. 2010;23(2):299-323. 
3. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory 
microbiology of patients with cystic fibrosis in the united states, 1995 to 2005. 
CHEST Journal. 2009;136(6):1554-60. 
4. Nelson A, De Soyza A, Perry JD, Sutcliffe IC, Cummings SP. Polymicrobial 
challenges to Koch’s postulates: Ecological lessons from the bacterial vaginosis and 
cystic fibrosis microbiomes. Innate Immunity. 2012;18(5):774-83. 
5. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, et al. The 
adult cystic fibrosis airway microbiota is stable over time and infection type, and 
highly resilient to antibiotic treatment of exacerbations. PLOS ONE. 
2012;7(9):e45001. 
6. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML, et 
al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of 
upper-airway specimens can misrepresent lung microbiota. Proceedings of the 
National Academy of Sciences. 2012;109(34):13769-74. 
7. Willner D, Haynes MR, Furlan M, Schmieder R, Lim YW, Rainey PB, et al. Spatial 
distribution of microbial communities in the cystic fibrosis lung. The ISME Journal. 
2011. 
8. van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, 
et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial 
communities. The ISME journal. 2010;5(5):780-91. 
9. Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, et al. 
Discerning the complexity of community interactions using a drosophila model of 
polymicrobial infections. PLoS pathogens. 2008;4(10):e1000184. 
10. Madan J, Koestler D, Stanton B, Davidson L, Moulton L, Housman M, et al. 
Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: 
Interaction between intestinal and respiratory tracts and impact of nutritional 
exposures. mBio. 2012;3(4). 
11. Stressmann FA, Rogers GB, Klem ER, Lilley AK, Donaldson SH, Daniels TW, et 
al. Analysis of the bacterial communities present in lungs of patients with cystic 
fibrosis from American and British centers. J Clin Microbiol. 2011;49(1):281-9. 
146 
12. Filkins L, Hampton T, Gifford A, Gross M, Hogan D, Sogin M, et al. The 
prevalence of Streptococci and increased polymicrobial diversity associated with 
cystic fibrosis patient stability. J Bacteriol. 2012. 
13. Twomey KB, O'Connell OJ, McCarthy Y, Dow JM, O'Toole GA, Plant BJ, et al. 
Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate 
virulence and persistence of Pseudomonas aeruginosa. The ISME Journal. 2011. 
14. Rogers GB, Skelton S, Serisier DJ, Van Der Gast CJ, Bruce KD. Determining 
cystic fibrosis-affected lung microbiology: Comparison of spontaneous and serially 
induced sputum samples by use of terminal restriction fragment length 
polymorphism profiling. J Clin Microbiol. 2010;48(1):78-86. 
15. Rogers G, Carroll M, Serisier D, Hockey P, Jones G, Bruce K. Characterization 
of bacterial community diversity in cystic fibrosis lung infections by use of 16s 
ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin 
Microbiol. 2004;42(11):5176-83. 
16. Rogers G, Hart C, Mason J, Hughes M, Walshaw M, Bruce K. Bacterial diversity 
in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) 
length heterogeneity PCR and 16S rDNA terminal restriction fragment length 
polymorphism profiling. J Clin Microbiol. 2003;41(8):3548-5. 
17. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, et al. 
Detection of anaerobic bacteria in high numbers in sputum from patients with cystic 
fibrosis. American journal of respiratory and critical care medicine. 2008;177(9):995-
1001. 
18. Tunney M, Klem E, Fodor A, Gilpin D, Moriarty T, McGrath S, et al. Use of 
culture and molecular analysis to determine the effect of antibiotic treatment on 
microbial community diversity and abundance during exacerbation in patients with 
cystic fibrosis. Thorax. 2011;66(7):579-84. 
19. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, et al. The 
airway microbiota in cystic fibrosis: A complex fungal and bacterial Community—
Implications for therapeutic management. PloS one. 2012;7(4):e36313. 
20. Sibley CD, Grinwis ME, Field TR, Eshaghurshan CS, Faria MM, Dowd SE, et al. 
Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PloS 
one. 2011;6(7):e22702. 
21. Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG. The genus Prevotella 
in cystic fibrosis airways. Anaerobe. 2010;16(4):337-44. 
147 
22. Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, Borneff‐Lipp M, et 
al. Antibiotic‐resistant obligate anaerobes during exacerbations of cystic fibrosis 
patients. Clinical Microbiology and Infection. 2009;15(5):454-60. 
23. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, Sarles J, et al. 
Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis 
patients. PLoS One. 2008;3(8):e2908. 
24. Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, Krismer B, et al. Relative 
contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung 
pathology in airways of patients with cystic fibrosis. Thorax. 2010;65(11):978-84. 
25. Thomassen M, Klinger J, Badger S, Van Heeckeren D, Stern R. Cultures of 
thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J 
Pediatr. 1984;104(3):352-6. 
26. Rogers G, Carroll M, Serisier D, Hockey P, Jones G, Kehagia V, et al. Use of 
16S rRNA gene profiling by terminal restriction fragment length polymorphism 
analysis to compare bacterial communities in sputum and mouthwash samples from 
patients with cystic fibrosis. J Clin Microbiol. 2006;44(7):2601-4. 
27. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, et al. 
Molecular identification of bacteria in bronchoalveolar lavage fluid from children with 
cystic fibrosis. Proceedings of the National Academy of Sciences. 
2007;104(51):20529. 
28. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects 
of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic 
fibrosis patients. J Clin Invest. 2002;109(3):317-25. 
29. Peters BM, Jabra-Rizk MA, Graeme A, Costerton JW, Shirtliff ME. Polymicrobial 
interactions: Impact on pathogenesis and human disease. Clin Microbiol Rev. 
2012;25(1):193-21. 
30. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, 
et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial 
eradication at birth. Science translational medicine. 2010;2(29):29ra31. 
31. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and 
bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis. 
1997;175(3):638-47. 
32. van de Weert-van Leeuwen, PB, Slieker M, Hulzebos H, Kruitwagen C, van der 
Ent C, Arets H. Chronic infection and inflammation affect exercise capacity in cystic 
fibrosis. European Respiratory Journal. 2012;39(4):893-8. 
148 
33. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine 
production in cystic fibrosis. J Allergy Clin Immunol. 1999;104(1):72-8. 
34. Ernst RK, Eugene CY, Guo L, Lim KB, Burns JL, Hackett M, et al. Specific 
lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. 
Science. 1999;286(5444):1561-5. 
35. Brumback LC, Davis SD, Kerby GS, Kloster M, Johnson R, Castile R, et al. Lung 
function from infancy to preschool in a cohort of children with cystic fibrosis. Eur 
Respir J. 2013 Jan;41(1):60-6. 
36. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. 
Decade-long bacterial community dynamics in cystic fibrosis airways. Proceedings 
of the National Academy of Sciences. 2012;109(15):5809-14. 
37. Ma L, Conover M, Lu H, Parsek MR, Bayles K, Wozniak DJ. Assembly and 
development of the Pseudomonas aeruginosa biofilm matrix. PLoS pathogens. 
2009;5(3):e1000354. 
38. Stapper AP, Narasimhan G, Ohman DE, Barakat J, Hentzer M, Molin S, et al. 
Alginate production affects Pseudomonas aeruginosa biofilm development and 
architecture, but is not essential for biofilm formation. J Med Microbiol. 
2004;53(7):679-90. 
39. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, 
et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis 
patients. Pediatr Pulmonol. 2009;44(6):547-58. 
40. Ghio AJ, Roggli VL, Soukup JM, Richards JH, Randell SH, Muhlebach MS. Iron 
accumulates in the lavage and explanted lungs of cystic fibrosis patients. Journal of 
Cystic Fibrosis. 2012. 
41. Lamont IL, Konings AF, Reid DW. Iron acquisition by pseudomonas aeruginosa 
in the lungs of patients with cystic fibrosis. Biometals. 2009;22(1):53-60. 
42. Parkins MD, Sibley CD, Surette MG, Rabin HR. The Streptococcus milleri 
group—an unrecognized cause of disease in cystic fibrosis: A case series and 
literature review. Pediatr Pulmonol. 2008;43(5):490-7. 
43. Duan K, Dammel C, Stein J, Rabin H, Surette MG. Modulation of Pseudomonas 
aeruginosa gene expression by host microflora through interspecies communication. 
Mol Microbiol. 2003;50(5):1477-91. 
44. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial 
infection and adaptation in cystic fibrosis. Clin Microbiol Rev. 2011;24(1):29-70. 
149 
45. Bjarnsholt T, Nielsen XC, Johansen U, Nørgaard L, Høiby N. Methods to classify 
bacterial pathogens in cystic fibrosis. Cystic fibrosis: diagnosis and protocols, 
vol.II.Methods and resources to understand cystic fibrosis. 2011:143-71. 
46. Shinzato T, Saito A. A mechanism of pathogenicity of Streptococcus milleri 
group” in pulmonary infection: Synergy with an anaerobe. J Med Microbiol. 
1994;40(2):118-23. 
  
 
 
